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ABSTRACT 
Serological assessment vjas carried out to 
construct the antibody profiles in vivax malaria in a 
population sample comprising of 63 individuals belonging to 
different age groups from the Aligarh District - an area 
endemic for malaria. Indirect fluorescent antibody (IFA) 
tests were used to detect and estimate the IgG, IgM and IgA 
antibodies in the sera samples. A titre of 1:20 was taken 
as an index of an active malaria infection. 
On an overall basis, antimalarial IgM levels were 
found to be higher in most cases of slide-proven vivax 
malaria, as also in significant amounts in the healthy 
controls of all age groups. Initial results were fairly 
suggestive of an active transmission of malaria in the study 
area. 
Antimalarial IgG titres were found to show an 
increasing trend after 2 years of age. In adults, IgG leveLs 
were similar in slide-proven cases of vivax malaria and in 
healthy controls, indicating not only the prevalence of the 
disease in the area under investigation but also a 
significantly higher level of humoral Immunity among the 
resident adults. Presence of antimalarial IgA was also 
recorded in a few cases, the significance of which was not 
quite clear on the basis of this investigation. IgM levels 
Cix) 
were found to be less affected by chemotherapy as compared 
to IgG levels. The significance of this finding, in relation 
to the serological status of the individuals exposed 
naturally to malaria, has been discussed in the appropriate 
section of this dissertation. 
INTRODUCTION 
.1 
Malaria is a disease caused by sporozoa of the 
genus Plasmodium. It is characterized by fever, which is 
often periodic, chills and sweating, varying degrees of 
anaemia, splenic enlargement, and various syndromes 
resulting from the physiological and pathological 
involvement of certain organs including the liver and the 
kidneys (1). 
Malaria remains the most important of all the 
parasitic infections in terms of global impact and it is a' 
threat to almost half the world's population. Malaria is 
widely endemic in the less developed countries in the 
tropics, where children who constitute up to half of the 
population are beset with all manner of insults to their 
health and well-being that start prenatally and continues 
throughout the childhood (2). In India it is universally 
recognized as one of tjip most important health problems and 
constitutes an adverse factor in the social and economic 
advancement of the country (3,4). 
1.1 HISTORICAL REVIEW 
Human malaria is probably as old as mankind. 
Garnham in 1966 (5) considered the collateral evolution of 
malarial parasites of the primates with that of their hosts, 
starting with their vertebrate hosts. The first prosimian 
primates evolved some 50 million years ago. These lemur-
like animals were probably associated with the appearance of 
Hepatocystis and eventually with the quartan groups of the 
malarial parasites. Over a period of a million years series 
of evolutionary changes occurred in the original quartan 
group of malarial parasites and between 10 and 2 million 
years ago the present sub-genus Laverania emerged. 
Fossil mosquitoes were found in geological strata 
30 million years old and there is no doubt that they have 
spread infection throughout the warmer regions of the globe, 
long before the dawn of history (6). 
Prehistoric man in the Old World was subject to 
malaria. It is probable that the disease originated in 
Africa which is believed to be the cradle of the human race. 
Malaria followed with the wake of human migrations to the 
Mediterranean shores, to Mesopotamia, the Indian peninsula 
and South East Asia. How malaria established itself in the 
New World is still a subject of speculation (7). 
The earliest indications of a human disease 
suggestive of malaria came fom ancient Egypt. The consensus 
is that in prehistoric times, malaria was very common in the 
southern valley of the Nile, accessible from the vast 
hinterland of Tropical Africa. Enlarged spleens probably due 
to malaria have been found in mummies about 3000 years old 
and splenomegaly with fever has been mentioned in Ebers 
Papyrus of 1570 BC (7). 
Hippocrates in 400 BC (8) gave the first accurate 
clinical description of the disease. He had for the first 
time mentioned the classical triad of chills, fever and 
sweating and some complications of the disease. He further 
analysed the characterstic periodicity of various forms of 
malaria and associated splenomegaly with the endemicity of 
malaria and its topographical aspects (9). 
References to seasonal and intermittent fever 
exists in the ancient Assyrian, Chinese and Indian religious 
and medical texts. Non-medical writers alluded to fevers 
that affected those who lived in marshy areas. These 
specific fevers known in England as "agues" received in the 
18th century the Italian name "mal'aria" meaning bad air, 
since it was widely believed that their cause was related to 
foul air common near the marshy areas. The French term 
"paludisme" indicating a close connection with the swamps 
came much later (1). 
The most important events in the history of 
malaria took place towards the end of the 19th century when 
in 1880 Laveran, a French army surgeon first saw and 
described malaria parasites in human erythrocytes. Soon 
after that Romanowsky in Russia developed a new method of 
staining, which coupled with the improvement of microscopes 
accelerated and made studies on Plasmodia easier <1). 
Ronald Ross working in India in 1897 identified 
mosquitoes as the vectors of malaria parasites. The whole 
complex picture of the cycle of development of malaria 
parasites in man and in the Anopheles mosquito became 
clearer as a result of further studies by the Italians, 
namely Amigo Bignami, Giuseppe Bastianelli and Battista 
Grassi in 1898-99. Confirmation of the fact that malaria is 
transmitted by female Anopheles mosquito was based on the 
combined field experiments carried out by Patrick Hanson and 
and his colleagues near Rome and in London in 1900 (10). 
During the 20th century much research was devoted 
to malaria control. Larvicides in the form of oil of Paris 
green were introduced for preventing the breeding of 
mosquitoes in stagnant waters. At the beginning of the 
Second World War, Paul Muller of Switzerland discovered the 
high insecticidal action of a synthetic compound, dichloro-
diphenyl-trichlor-ethane, which was given the abbreviated 
name, DDT (1). 
The first therapeutic advance in malaria occurred 
at the beginning of the seventeenth century when Juan Lopez 
a Jesuit missionary recorded the use of the 'Peruvian bark' 
for treatment of fevers by the Peruvian Indians. In 1742, 
Carlos Linneaus in Sweden described the tree and gave it the 
name Cinchona. Further clinical trials on the use of 
Cinchona were carried out by Cardinal Juan de Lugo in 1643 
in Rome and by Morton and Sydenham in England to prove its 
efficiency. Pelletier and Caventon in 1820 for the first 
time succeeded in extracting two alkaloids which they named 
"quinine" and "cinchonine". Out of these quinine was found 
to be a more effective antimalarial (1,6,10). 
Further efforts were made towards developing cheap 
and effective drugs against malaria. This was brilliantly 
accomplished in 1924 by Schulemann's discovery of pamaquine. 
Subsequently, in 1930 a much more valuable drug- mepacrin 
was prepared by Kikuth, Mietzch and Mauss. Other valuable 
synthetic drugs were developed by the Germans, French, 
Americans and the British in 1934 (Chloroquine), 1945 
(Proguanil), 1946 (Amodiaquine), 1950 (Primaquine) and 1951 
(Pyrimethamine) (1). 
These synthetic drugs were successful due to their 
potency against malaria parasites and their cheap purchasing 
cost until the early 60's when the first report of 
chloroquine resistance against Plasmodium falciparum was 
reported from Columbia and Brazil. Similar reports of 
chloroquine resistance came subsequently from various other 
parts of the world. These findings led to more reseach 
towards developing alternative effective antimalarials. 
Series of drugs were developed including mefloquine in 1971-
75, amino-alcohol compounds as possible antimalarials were 
developed by the United States Walter Reed Institute for 
Research. In 1979-82 the antimalarial called qinghaosu 
(artemesinine) was developed followed by the development of 
a series of other derivatives of 8-amino-quinolines with 
high activity for treatment of relapsing malaria in 1976-83 
(1,10). 
Another landmark in the advance of the knowledge 
of malaria came in 1976 when Trager and Jensen discovered 
the continuous in vitro culture technique of E_^  falciparum 
in the U.S.A. (1). 
With the development of the science of 
biotechnology the isolation of mRNA from E^ falciparum and 
cloning of its DNA in a bacterium (Escherichia coll) was 
made possible in 1983 (10). The above advances opened up 
many possibilities for research towards the knowledge of 
malaria, its treatment, control and finally eradication. 
1.2 THE MALARIA PARASITE 
The micro-organisms causing malaria are commonly 
referred to as malaria parasites; this term is restricted to 
the family Plasmodiidae within the order Coccidiida, 
suborder Haemosporidiidea which comprises various parasites 
found in the blood of reptiles, birds and mammals (1). 
The genus Plasmodium is peculiar in ; 
1. One type of asexual multiplication by division 
occurring in parenchymal cells of the liver of the 
vertebrate host (exo-erythrocytic schizogony), and; 
2. The mosquito hosts are of various species of Anopheles. 
1.2.1 Species and Strains 
The family Plasmodiidae contains the single genus 
Plasmodium. which is divided into nearly 120 species 
including atleast 22 species found in primate hosts, 19 in 
rodents, bats or other mammals and about 70 species in birds 
and reptiles (1) . 
The Plasmodia of the primate hosts are divided 
into 3 subgroups, within the sub-genus Plasmodium, there are 
four groups classified mainly according to the periodicity 
of their erythrocytic schizogony. 
There are four generally recognized species of 
malaria parasites of man; three species of Plasmodium are 
peculiar to man: E_^  vivax. P . ovale and E^ falciparum. One 
species is common to man and African apes - E_^  malariae. 
P • malariae (Laveran, 1881) 
P• vivax - (Grassi and Feletti, 1890) 
E^ falciparum ~ (Welch, 1897) 
£^ ovale - (Stephens, 1922) 
Finally, several simian species of Plasmodium are 
rarely found in man including E^ kpowlesi and EL^  simian as 
zoonoses. L cvnomologi and IL bastianelli are identified as 
accidental laboratory acquired infections while £^ jjlLLi and 
P• schwetzi have been known to cause experimental infections 
(1). 
It is not uncommon to observe that some 
morphological or other characterstics of one well defined 
species of malaria parasites may vary somewhat from one 
geographical area to another. The biological variations may 
be so distinctive that they provide an acceptable basis for 
referring these parasite populations as strains (1). 
1.2.2 Life Cycle 
The life cycle of the parasite is essentially 
similar in all species of Plasmodia. 
Cynlf! in man : (Rohi y:ngnny n-r Hy;Ryii»1 pycl e) 
1. Pre-erythrocytic phase. 
The parasite is introduced into the body by a bite of 
the mosquito, as thin, motile, spindle shaped 
sporozoites. These stay in the blood circulation for 
approximately half an hour and then enter the 
parenchyma cells of the liver. During the succeeding 
5-7 days the parasites develop into large multinucleate 
schizonts which mature and liberate small, round, 
mononucleate merozoites (1,11,12). 
2. Exo-erythocytic phase. 
About a decade ago it was discovered that the 
sporozoites of the relapsing type of malaria, namely P. 
vivax and L ovale differentiate either into 
hypnozoites or into developing tissue schizonts in 
varying proportion depending on the strain. The 
hypnozoites remain dormant in the hepatocytes as uni-
nucleated forms for considerable periods. At a 
predetermined time the hypnozoites begin to grow and 
undergo exo-erythrocytic schizogony, forming a wave of 
merozoites that invade the blood, and produce a 
clinical relapse, although the parasites have been 
removed from the peripheral blood (1,11,12), 
3, Erythrocytic phase. 
In this phase, the merozoites enter the red cells and 
grow as trophozoites. These are more or less rounded 
bodies, some of which contain a vacuole which displaces 
the cytoplasm to the periphery, while the nucleus is 
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situated at the pole. These young parasites are known 
as the ring forms of the trophozoites. Trophozoites of 
P• vivax show lively amoeboid movement. At first the 
trophozoites produce the ring forms, small, round 
structures clear in the centre with a chromatin dot at 
one side. These develop into mature trophozoites, 
large, irregular structures, usually containing dark 
granules of haemozoin, a product of haemoglobin 
digestion, occupying most of the red cell volume. When 
fully developed the nucleus of the trophozoites begins 
to segment and it becomes a schizont. A mature schizont 
consists of 6-32 small, round or oval merozites, the 
number varying with the species. In E_^  vivax the mature 
schizont contains an average of 12-18 merozoites. In P. 
falciparum malaria the infected red cells usually 
disappear from the peripheral blood before the 
trophozoites are mature and schizogony occurs in the 
capillaries of the internal organs. Finally, when the 
process of schizogony is completed the red cell bursts 
and merozoites are released into the bloodstream where 
they attack new red cells and repeat the asexual cycle. 
The erythrocytic schizogony is repeated over and over 
again leading to a progressive parasitemia until slowed 
down by the immune responses of the host or 
chemotherapy. The paroxysms of fever occur when the 
merozoites are released in the blood. The morbidity and 
11 
mortality in malaria is due to the release of 
parasitic material and parasites in the erythrocytic 
phase during the course of the disease (1,11,12). 
4. Gametocyte production. 
After parasitemia has been present for a few days some 
merozoites, instead of developing into schizonts, 
develop into sexual cells or gametocytes. These may be 
male gametocytes (microgametocytes) or female 
gametocytes (macrogametocytes). Ho further development 
of these cells occurs in the human body. In E_^  vivax 
gametocytes may appear in the blood within three days 
after the appearance of the asexual parasites in the 
blood. The presence of gametocytes in the blood is 
essential in rendering the patient infective to the 
mosquitoes and for the continuity of the life cycle of 
parasites in the invertebrate hosts (1,11,12). 
Cycle in the mosquito Usporogonv or sexual cvcle> 
When a female Anopheles mosquito ingests the blood 
of the human host with gametocytes in circulation, the red 
cells set the parasites free in the mosquito's stomach. The 
macrogametocyte matures to form a female macrogamete while 
the microgametocyte develops 4-8 flagellum like structures 
which break off and swim away as male microgametes. The male 
12 
and female gametes unite to form a zygote which rapidly 
becomes a motile cell known as ookinete. This penetrates the 
muscle of the stomach wall where it becomes a rounded oocyst 
inside which thousands of spindle shaped sporozoites 
develop. The cyst finally ruptures liberating the 
sporozoites into the body cavity from where they find their 
way into the salivary gland of the female Anopheles which 
now becomes infective. When the mosquito feeds on the human 
blood after piercing the skin the sporozoites are injected 
into the wound and pass into the bloodstream of the 
vertebrate host, thus continuing the life cycle in man 
(1,12). 
1.3 EPIDEMIOLOGY AND GEOGRAPHICAL DISTRIBUTION 
Malaria is one of the most widespread of all 
parasitic diseases. It is found in regions lying roughly 
between latitudes SO^N and 40°S. The distribution of the 
plasmodial species is not uniform. Vivax malaria is 
widespread in the tropics and subtropics and in some 
temperate regions, sparing the Negroes of West Africa. It is 
present in areas of the Middle East, Iran, Pakistan, 
Bangladesh, India, Sri Lanka, Burma, Thailand, Malaysia, 
Indonesia, East and Central Africa and Central and South 
America. Falciparum malaria is found commonly in warm moist 
climates. It is the dominant form of malaria in the tropical 
West, Central and parts of East Africa, in regions of the 
13 
Middle East, South, Central and Worthern India, in parts of 
Bangladesh and Pakistan and in Burma, Thailand, Laos, 
Malaysia and Indonesia. It occurs in the Philippines, 
certain Pacific Islands, Haiti in the Carribean Islands, and 
in Central and South Airierica. Quartan malaria caused by £_^  
palariae occurs throughout the tropics, chiefly in Africa, 
South America, India, Sri Lanka and Malaysia. It is not as 
common as either vivax or falciparum malaria. Ovale malaria 
is uncommon. It occurs in East, West, and Central Africa, 
parts of North East Africa, and in South America (13). 
1.3.1 Endenicity 
Malaria is described as endemic when there is 
constant incidence of cases over a period of many successive 
years. Malaria in a community may either be stable or 
unstable. Stable malaria occurs in regions in which there is 
a constant, repeated infection. The population has a high 
degree of immunity and epidemics do not occur. Unstable 
malaria occurs in regions in which transmission is 
intermittent, inadequately protected by drug suppression or 
vector control. In such areas the population has a varying 
degree of immunity and epidemics are liable to occur (13). 
Endenic nalaria : may be present in various degrees and the 
following classification of it is continuously used: 
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Hvpoendemicitv : denotes areas where there is little 
transmission and the effects of malaria are on all the 
age groups. 
Hesoendemicjtv : is found typically among small rural 
communities in the subtropical zones with varying 
intensity of transmission depending on local 
circumstances. 
Hypigrendemici tv ; is seen in areas with intense but 
seasonal transmission where the immunity is 
insufficient to present the effects of malaria on all 
age groups. 
Holoendemicitv : denotes a perennial transmission of 
the disease resulting in a considerable degree of 
immune responses in all age groups, but particularly in 
the adults. 
1.4 CLINICAL DIAGNOSIS OF MALARIA 
In the clinical diagnosis of malaria, and of 
paramount importance, is the eliciting of a geographical 
history in the routine interrogation of all patients; other 
points of interest are the ethnic origin of the patients and 
a history of previous attacks of malaria (4,6). 
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1.4.1 General Features of an Acute Attack of Malaria 
The clinical manifestations of malaria are 
extremely diverse and may range in severity from a mild 
headache to the development of acute pulmonary oedema in 
moribund patients. However, a majority of attacks develop a 
well recognised pattern in which bouts of fevers alternate 
with asymptomatic periods. Incubation period varies from 
species to species. They tend to be between 9 to 14 days in 
^ falciparum. 12 to 17 days for E_ vivax, 30 to 40 days for 
E^ malariae and 13 to 17 days for E^ ovale (7). 
The classical malaria paroxysm comprises of three 
successive stages. The cold stage starts with rigors and a 
feeling of intense cold. This stage lasts between 15 to 60 
rv 
minutes. The hot stage follows when the feeling of itense 
cold gives way to one of distressing heat. The temperature 
may rise upto 41''C. This stage lasts for 2 to 6 hours. The 
hot stage is followed by a terminal sweating stage when the 
patient breaks out in profuse sweat, so that his bedding 
becomes drenched. The temperature falls rapidly, often below 
normal. This stage lasts from 2 to 4 hours. (1). 
Representatives of all development forms of 
asexual paasites from the early ring to the mature schizont 
may be recognised in the peripheral blood at any one time, 
although one stage usually preponderates once the usual 
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periodicity has been established. The density of parasitemia 
in vivax malaria seldom exceeds 2% of the infected 
erythrocytes. Gametocytes may be found after the infection 
has been present for a week (1,13). 
The trend of the classical features are more 
defined in vivax malaria. The primary attack is composed of 
a number of paroxysms occurring at 48 hours interval. A 
single untreated attack of vivax malaria may last for a few 
weeks to three months or more with repeated paroxysms before 
spontaneous clinical cure occurs. The duration depends on 
the multiplication rate of the parasite strain involved and 
on the counteraction of the immune responses of the host. 
1.4.2 Relapses in Vivax Malaria 
A relapse is a renewed occurrence of clinical 
symptoms and parasitemia after a time considerably greater 
than the intervals between periodic paroxysms of the primary 
infection. The period during which the malaria infection is 
not evidenced clinically by any symptoms of disease are 
known as latency. Parasite latency has been known in vivax 
malaria in which stage the parasites are absent from the 
blood but are present as exoerythrocytic forms in the 
patient's liver. The dormant hepatic forms are known as 
hypnozoites and are the direct descendents of sporozoites 
which were the precursors of the primary attack of the 
disease. 
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In about 60% of untreated or inadequately treated 
cases of vivax malaria, clinical symptoms recur after a 
period of quiescence, the length of which depends largely on 
the particular strain of the parasite. Renewed clinical 
activity is seen either during the first 8 to 10 weeks after 
the primary attack, when it is designated as a short-term 
relapse, or around 30 to 40 weeks after the primary attack 
when it is referred to as a long-term relapse. 
The clinical features of a relapse are similar to 
those of the primary attack, except that the initial period 
of irregular fever is absent. The defined periodicity of 
paroxysms occurring every 48 hours are established from the 
start. The relapse is commonly less severe and of a shorter 
duration than the ^ primary attack. It has been suggested that 
various adverse factors including cold, fatigue, trauma, 
pregnancy and illness act as a stimulus for relapses. 
1.5 LABORATORY DIAGNOSIS OF MALARIA 
Irrefutable evidence of malaria is the 
demonstration of the parasite in stained blood films on 
microscopy by a competent and experienced person. An 
indirect evidence of malaria infection is made through 
serology (synonymous : immunodiagnosis), which has become of 
practical value in the recent years (1). 
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1.5.1 Microscopy 
The definitive diagnosis of malaria has 
historically been based on the detection of parasites in the 
blood, and still today it supercedes all other laboratory 
diagnostic methods of malaria detection (14). 
Two kinds of blood films, a thin film and a thick 
film could be made on glass slides of 25mm x 75 mm 
dimensions for detecting malaria parasites. Details of smear 
preparation are given in the Appendix. 
Romanowsky in 1890 discovered an effective 
staining technique of Plasmodia. This coupled with the aid 
of a modern high powered microscope leaves a competent 
microscopist to marvel at the accuracy with which the 
parasites could be visualised. Two types of stains being 
popularly used now in most laboratories are the Leishman and 
Giemsa stains. More details on instruction for preparation 
of stain used in this study can be found in the Materials 
and Methods section of this literature. 
Having stressed the importance of blood film 
microscopy in the diagnosis of malaria, it has certain 
limitations which must be appreciated and include : 
1. The difficulty in evaluating the significance of 
parasitemia in holoendemic regions where asymptomatic 
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parasitemia occurs in as many as 60-80% children and 
20% adults. 
2. Inappropriate self medication, which is a common 
practice in the developing countries or chemotherapy 
administered before and during the period when blood 
smear is made, suppresses parasitemia and reduces 
malaria parasites below detectable threshold of 
microscopy (15,16). 
3. Inspite of active disease, microscopy shows negative 
results if blood films are made during the apyrexial 
interval, particularly in infections where P. 
falciparum matures synchronously and the parasites in 
the schizont stage disappear from the peripheral blood 
and sequester in the capillaries of the internal organs 
(15). 
4. Negative results on microscopy can occur in all cases 
of primary infection during the first two or three days 
of the disease (15). 
In the last two possibilities, serial blood films 
taken on intervals of 6 to 12 hours are required as long as 
diagnosis remains in doubt or until recovery supervenes. 
1.5.2 Innunodiagnosis 
Immunodiagnosis of malaria has received much 
attention during the recent years. The principle of immuno-
diagnosis is the detection of specific antimalarial anti-
bodies. Since malarial antibodies are found in the sera of 
normal population in endemic areas, the test has to be 
quantitative when it is desired to distinguish between 
current, recent or past infections. However, measurement of 
antibody response has no part to play in the diagnosis of 
acute malaria, but progress may in the due course lead to 
immunological diagnosis of current infections (17). 
Antibodies are first detected a few days after 
infection of the blood and antibody levels rise quickly to a 
plateau which is maintained for sometime after which a slow 
decline occurs (18,19,20). The exact time course of these 
events depends upon the species of the infecting malarial 
parasite and upon the previous experience of the host. In 
vivax malaria in which long term relapses can occur, 
antibody levels can fall between relapses but seldom 
disappear completely. However, after spontaneous resolution 
of the infection or following therapeutic cure, antibodies 
decrease rather rapidly and may become undetectable 
(17,21,22,23,24,25). Almost all the conventional serological 
methods have been tried at one time or another for assay of 
malarial antibodies, but the only techniques which have 
found wider applications are agar-gel diffusion test, 
indirect haemagglutination test, indirect fluorescent 
antibody test, enzyme linked imiriunosorbent assay and radio-
immunoassay . 
Agar-Gel Diffusion Test 
In this method the test sera are allowed to 
diffuse against soluble antigen in agar-gel. The presence 
and number of precipitin bands formed are an indication of 
the antibody contents of the test sera. The prevalence and 
number of precipitin bands increase with age, reflecting the 
exposure and development of immunity to malaria (15). The 
experience to date suggests that agar-gel diffusion is an 
excellent tool for the analysis of the multiple antigen-
antibody responses in a community subjected to malaria. 
However owing to its rather low sensitivity and slowness it 
cannot be considered as being suitable for immunodiagnosis 
of malaria in the infected individual (17). 
Indirect Haenagglutination (IHA) Test 
This method is based on the agglutination of 
malarial antigen-coated carrier erythrocytes by malarial 
antibody. Crude soluble extracts of malarial parasites are 
used as the antigen and are fixed in vitro on to carrier 
sheep or human erythrocytes. The antigen employed popularly 
for this purpose is derived from L-. knowlesi since it can be 
readily available from the blood of the rhesus monkey, 
Hacaca mulatta. after infecting it with £^ knowlesi where it 
is capable of producing high parasitemia (26,27,28,29,30,31, 
32). Dilutions of the test sera are then reacted with these 
sensitised erythrocytes. The pressure and amount of malarial 
antibody present are indicated by the serum dilution which 
leads to agglutinations. Negative results do occur as a 
result of non-specific agglutination factors which is a 
feature of some sera from tropical areas. It has also been 
reported that the test is rather insensitive at detecting 
antibodies in the early phases of a primary malaria 
infection, especially in young children which limits its 
usefulness (17). 
Indirect Fluorescent Antibody (IFA) Test 
The indirect method of immunofluorescence has been 
the preferred method of malarial antibo(;iy determination for 
the past decade (17,33,34). In this method the antigen 
consists of drops of infected blood dried on glass slides. 
These slides are reacted with dilutions of the test serum 
sample. After washing, the slides are reacted with a 
solution of fluorescein-labeiled antiglobulin, and after 
another washing are examined on a fluorescent microscope. 
Antibodies in the test serum reacts with the malarial 
parasites in the blood smears and the fluorescein-labelled 
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antiglobulin then becomes fixed to the antigen-antibody 
complex. Antibody containing sera are indicated by 
fluorescence of the parasites in the slide antigen. The 
amount of antibody is shown by the last serial dilution that 
reacts and is given as the titre value for the sample 
concerned (17). Generally, fluorescence at a dilution of 
serum at 1:20 is regarded as the lowest positive titre and 
all dilutions over this titre showing fluorescence are 
indicated as a positive test for active malaria (1,26>. 
Inspite of its limitation.^, indirect fluorescent antibody 
test has been widely and successfully used both for 
immunodiagnosis and seroepidemiology (21,26,35,36). 
It has been confirmed that serological cross-
reactivity occurs between E_^  falciparum and E_^  vivax (37). 
Since E_^  falcipariiyi can be cultured in vitro (38), its 
antigens can be obtained in greater quantities than antigens 
of E_^  vivax for which no efficient culture technique is 
currently available. With the discovery of serological 
cross-reactivity between the two species, sera from P. 
falciparum infected patients can be cross-reacted with P. 
vivax antigen and vice versa (37). 
Enzyne Linked Immunosorbent Assay (ELISA) 
This test is analogous in concept to the IFA test. 
Soluble antigen from malaria infected blood is coated on to 
a plastic surface which is reacted with the test serum 
sample. An enzyme labelled antiglobulin is then added, 
followed by a chromogenic enzyme substrate. The amount and 
rate of colour development are proportional to the amount of 
antibody in the test serum. The results can be read visually 
or with more accuracy on a photometer (17). 
This technique is rather easy to perform, 
especially in the microplates and makes possible the 
processing of large number of samples. Its disadvantage lies 
in its inefficiency in detecting low antibody levels 
especially in children (39,40). ELISA has been successfully 
used in the serodiagnosis of vivax malaria (41). 
Radioinuunoassay (RIA) 
Radioimmonoassay can be performed in the same 
manner as ELISA, merely by substituting the enzyme label 
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with l-^'^"-' on the anti-immunoglobulin. In the initial studies 
the malarial antigen was fixed on to carrier erythrocytes 
but in the later studies plastic tubes or plates have been 
used. Results are comparable with ELISA, but the short life 
of the labelled reagents and the expensive equipment needed 
neans that the test has little field value (17,42,43,44, 
45). 
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1.5.3 Recent Advances in Laboratory Diagnosis of Malaria 
Currently interest centres on the detection of 
circulating malarial antigen or parasite DNA as a 
diagnostic adjunct. The reliable detection of such 
circulating substances would be strong evidence of malaria 
even in the abscence of demonstratable peripheral blood 
parasitemia. As yet, however no test detects patent 
parasitemia more reliably than blood film examination and 
more sensitive methods are awaited, among which DNA probes 
hold considerable promise. 
The development of specific DNA probes for 
identification of E_.^  falciparum has been reported by various 
researchers (46,47). This method compared favourably in 
sensitivity with routine microscopy, detecting parasite 
densities as low as 40 parasites per >j 1 of blood. However, 
these methods require organic extraction of the sample DNA 
from the patients blood, which is impractical under field 
conditions and when handling large numbers of samples. 
Recently, modifications of the conventional DNA probe method 
in malaria diagnosis has been reported in which blood 
samples are spotted onto filtration membranes directly after 
lysis and do not require additional sample manipulation. 
This method offers the advantage of a standardised procedure 
that can be used in a batchwise fashion on a large number of 
samples. Thus, a single technician can process thousands of 
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samples per day as compared to about 60 blood smears by 
ordinary microscopy, besides eliminating the individual 
reader bias (46). 
Meanwhile, another advance that has been made in 
the laboratory diagnosis of malaria is the discovery of 
modified light microscopy by Kawamoto in 1991(48), who used 
fluorescence staining to detect malaria parasites in blood 
films, which is both sensitive, easier and less time 
consuming than ordinary Leishman or Giemsa staining. 
Fluorescence microscopy with a standard light microscope and 
a new interference filter which consists of a multi-layer 
excitation filter combined with barrier filter specially 
designed for the fluorescence stain, acridine orange, was 
used to detect malaria parasites in thin and thick blood 
films and rapid scanning of blood films was possible at a 
magnification of x 200 with the standardized lenses, 
indirectly. This may be a useful, economic system for rapid 
diagnosis of malaria. The interference filter was developed 
initially to look at fluorescein isothiocyanate (FITC) 
labelled immunofluorescence in the standard light microscope 
(49,50). This interference filter system designed for use 
with acridine orange in light microscope is useful, economic 
and easy to use for the laboratory diagnosis of malaria 
since inexperienced microscopists may have difficulty in 
reading blood smears, it is easier since artifacts and 
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pLgment dots which are troublesome in ordinary stains cannot 
be seen. 
Finally, Western Immunoblotting has also been used 
for detecting specific malarial antibodies of the IgG and 
IgM group, but the technique requires the use of expensive 
and sophisticated equipment and therefore impractical for 
routine diagnosis of malaria in the laboratory. 
1.6 IMMUNITY TO MALARIA 
The essential function of the immune system is 
defence against infection. Although the mechanisms of 
protective immunity against malaria are not fully 
understood, there is now ample evidence to indicate that 
humoral immune response (51), cell mediated immune responses 
and some non-specific factors are implicated in the 
potential of protective malaria immunity. Apart from these 
specific immune mechanisms, innate resistance of immuno-
genetic etiology is of significance in immunity to malaria. 
The various mechanisms of immunity to malaria have been 
explained briefly as follows: 
1.6.1 Innate Inmunity 
An early finding in the immunity to malaria was 
that some individuals without previous experience of malaria 
were innately refractory to infection. Later, attention was 
drawn to the singular resistance to infection by E_^  vivax 
that was possessed by Americans of Negroid descent. Such 
observations clearly established the evidence of important, 
non-immunological, possibly genetic mechanisms of resistance 
to malaria (51). 
The main possible mechanisms of the innate 
immunity to malaria parasites have been envisaged : 
1. The modification in the surface receptors of the 
erythrocytes to which the parasite adheres prior to 
penetration. For example, the Duffy blood group antigen 
(Fy"Fy") from the erythrocyte surface is refractory to 
the invasion by E_^  vivax. as found in the indigenous 
population of West Africa (1,51). 
2. Other immuno-genetic factors which may exclude blockage 
of the surface receptors of erythrocytes but affect the 
intracellular development of Plasmodia in the 
erythrocyte. These factors are listed as follows: 
(i) Modification in the molecular structure of 
haemoglobin, for example, in individuals 
possessing haemoglobin S (HbS) or sickle cell 
haemoglobin, the effects of L falciparum are 
modified and the severe pathological lesions 
seldom occur, even in children. This accounts for 
the high incidence of sickle cell anaemia in parts 
of Africa which are holoendemic for falciparum 
malaria. Erythrocytes with HbS show sickling in 
low oxygen conditions and has adverse effect on 
blood schizonts of E^ falciparum, possibly as a 
result of the pressure exerted on the parasite in 
the sickle cell, although the exact mechanism of 
action is still unclear (1). 
Foetal haemoglobin or haemoglobin F (HbF) is 
present in the infant at birth along with the 
normal haemoglobin in a ratio of 80% to 30% 
respectively. HbF is less suitable for the growth 
of EL^  falciparum, although its mechanism of action 
remains doubtful. HbF confers some protection, 
particularly in children with beta-thalassaemia 
during infancy and childhood. 
(ii) Another genetic factor which can impede the 
intracellular development of parasites is the 
deficiency of glucose-6-phosphate-dehydrogenase 
(G-6-PD). The gene involved in the deficiency of 
this erythrocytic enzyme is present in various 
areas where malaria is endemic. It has been shown 
that malaria parasites in G-6-PD deficient cells 
are more easily damaged by effects of oxidants 
than the non-G-6-PD deficient cells (52). 
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1.6.2 Acquired Innunity 
Acquired or adaptive immunity has two main 
features ; memory and specificity and includes the 
involvement of both cellular and humoral responses which 
have been well established in malaria immunity (53). 
Acquired immunity to malaria is species, strain and stage 
specific (10,54). It is widely accepted that host responses 
to Plasmodia are complex and involve a close collaboration 
between macrophages (non-specific components), T cells and B 
cells (54,61). 
Hunoral Innunity 
This involves the action of immunoglobulins. 
During malarial infections, there is a marked increase 
in serum immunoglobulin levels, part of which is 
specific to malaria parasites. However, there is a poor 
correlation between the immune status of the host and 
the levels of antimalarial antibodies. Much of this 
antimalarial antibody is non-protective (55). There is 
evidence suggesting that antiplasmodial activity can be 
demonstrated in the IgG, IgM and IgA fractions of the 
immune human sera (56, 57) and IgG being the 
predominant group in established infections. The 
humoral immunity tends to operate by restricting 
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parasite replication only at the asexual erythrocytic 
level and does not block invasion of liver cells by 
sporozoites or totally inhibit the successful 
maturation of intrahepatic stages of Plasmodia or 
gametocytogenesis (54). 
Humoral immunity could be passive or active. 
Passive immunity is acquired by the newborns through 
transplacental transfer of maternal antimalarial IgG. 
These antibodies persist in the early months of life 
and decrease with time, usually declining completely 
within nine months. This accounts for the rare cases of 
malaria among newborns. With time the immunity to 
malaria slowly develops and years after continuous 
exposure to different species and strains of Plasmodium 
results in development of high antimalarial antibody 
titres among individuals in malaria endemic areas. It 
has been observed that children between ages of 6 
months to 5 years are most susceptible to severe 
clinical disease. By adulthood the infected individuals 
show that little parasitemia may continue although the 
illness ends. It is also short lasting because immunity 
wanes without reinfection (55). 
Antibodies however do not prevent infection but may 
prevent severe disease in the immune individuals which 
can be observed in mild clinical symptoms in relapses 
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after the primary attack of malaria. The inefficiency 
to kill malaria parasites completely through humoral 
involvement is probably due to the characteristic 
specific nature of antibodies, which are protective 
when the individual is challenged repeatedly by a 
homologous strain of the parasite, though some 
protection is also evident towards heterologous strain 
of the parasite (10). 
Cellular Innunity 
Cellular or cell mediated immunity involves the 
action of T cells on the parasites and is more 
effective in protection against malaria. Plasmodia 
being intracellular parasites evade the action of 
antibodies and complement and require to be destroyed 
through the action of T cells which react only with 
antigens associated with the hosts cell surface. Cell 
mediated immune responses and the pivotal role of T 
cells are implicated in potential of protective malaria 
immunity (58,59). In immunity to malaria T cells play a 
crucial role in regulating antibody production apart 
from giving rise to antibody-independent, non-specific 
cellular immunity (60). 
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1.6.3 Non-Specific Factors in Immunity to Malaria 
This is the first line of action by the immune 
system and precedes the development of specific mechanisms 
of immunity. The non-specific factors include neutrophils 
and macrophages, both of which are phagocytic cells and act 
independently before any specific immune components are 
developed. 
T cells are the key cells in inducing non-specific 
immunity. Their significant functions in immunity to malaria 
are listed as follows (54): 
1. Attracting and activating macrophages which are able to 
destroy the intracellular malaria parasites through 
oxidative mechansisms following phagocytosis. Activated 
macrophages are also capable of producing a substance 
known as Tumour Necrosis Factor (THF) which is capable 
of destroying malaria parasites. 
2. Sensitised T cells are a source of interferon which has 
a potent inhibitory effect on the hepatic stages of the 
PlasgiQdium. 
3. Interleukins are a soluble substance produced by the T 
cells or activated macrophages and show protective 
effect against malaria. 
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A significant finding in this context is that the 
epitopes recognized by human T cells reside within the 
conserved regions of the parasite which hampers the 
recognition of the immunogen by the T cell. This has 
important implication for designing an effective merozoite 
vaccine (62). 
L.7 CONTROL 
Control of malaria can be brought about by 
chemotherapy, chemoprophylaxis, use of insecticides, 
biological control, personal protection other than chemo-
prophylaxis and the introduction of antimalarial vaccines 
(63). 
These are discussed below : 
1.7.1 Drugs 
The ideal antimalarial drug is effective against 
all forms of malaria, non-toxic, non-terratogenic and cheap. 
The major groups of drugs that are available are considered 
below : 
Cinchona Alkaloids : Significant extracts of Cinchona 
bark are quinidine and quinine, both of which are highly 
active against the blood stages of all forms of Plasmodia. 
Neither has activity against hepatic stages of the 
Plasmodium and, therefore, cannot be used for radical 
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treatment. Its toxicity prevents its use for 
chemoprophylaxis. However, it is used effectively for the 
treatment of chloroquine resistant Plasmodia. These are the 
oldest non-synthetic antimalarials known (64). 
Chloroquine It is a synthetic agent of the 4-amino-
quinoline series. It is highly active against the asexual 
stages of Plasmodia, but not active against hepatic stages 
and cannot be used for radical treatment. This drug can be 
used both for therapeutic and prophylactic purposes. 
Chloroquine was the ideal schizontocidal drug and used 
extensively until 1960's, when resistance against the drug 
by E_^  falciparum was first noticed. Over the period of time 
resistance to chloroquine by E^ falciparum has spread 
rapidly and extensively. However, in areas where chloroquine 
resistance is not pronounced it is still the drug of choice 
against malaria (82). However, inspite of the emergence of 
chloroquine resistant strains of E_^  falciparum it is 
interesting to note that it is effective against all the 
other species of Plasnodiugi (64). 
Amodiaquine : Like chloroquine, amodiaquine is a 4-
aminoquinoline with the same mode of action and spectrum of 
activity. Due to its toxicity it should not be used for 
malaria prophylaxis. However, it remains in widespread use 
for treatment of chloroquine resistant infections (64). 
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Mefloquine : It is a quinoline methanol active against the 
blood-borne asexual stages of all species of human malaria 
parasites, 
It is effective against certain chloroquine resistant and 
quinine resistant strains of E^ falciparum. Unfortunately, 
resistance to mefloquine has already been reported, although 
the drug is not widely available. It is usually administered 
in combination with sulphadoxine and pyrimethamine (64). 
E'rinaquine : This remains the only drug in current use 
which has activity against exoerythrocytic stages of 
infection and is thus able to achieve radical cure of vivax 
and ovale malaria, but it has no effect on the asexual blood 
forms of the parasite at therapeutically used doses (64). 
E'roguanil : The biguanides proguanil and its analogue 
chlorproguanil are active against the asexual blood stages 
of all species of human malaria, but the clinical response 
is slow and this limits the usefulness of the drug in the 
treatment of acute infections. Consequently, proguanil has 
been chiefly used for chemoprophylaxis. It is one of the 
safest antimalarials and it has seldom been implicated in 
serious toxicity (64). 
Pyrieethamine : It is structurally related to the 
biguanides and its range of antimalarial activity is similar 
to the biguanides and used primarily for malaria 
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prophylaxis. Unlike biguanides, pyrimethmine has largely 
been used in combination with other drugs: with dapsone as 
Maloprim and with sulphadoxine as Fansidar. Occasional 
reports of pyrimethamine associated foetal deformity have 
been reported (64). 
Dapsone : This is a diamino-diphenyl-sulphone and is 
schizontocidal for all forms of malaria, especially P. 
falciparum. Because of its slow onset of action its 
usefulness in the treatment of acute infections is limited 
and is principally been used in combination with 
pyrimethamine for malaria prophylaxis (64). 
Sulphonanides : These are used regularly for the 
treatment of bacterial infections, but in combination with 
other agents they have useful antimalarial activity. Long 
acting sulfonamides such as sulfadoxine have been widely 
used as antimalarials for example in Fansidar. However, 
hypersensitivity is one of the well documented adverse 
effect of the drug (84). 
Qinghaosu (Arteuesinine) This sesquiterpene lactone 
derivative of the herb Artemisia annua is still under 
investigation, and clinical trials have yielded very 
promising results. It is a blood schizontocide against 
chloroquine sensitive as well as chloroquine resistant 
strains of E_ falciparum (64). 
Halofantrine : It is a phensnthrenemethanol and is an 
upcoming antiraalsrial still under investigation and not 
widely available for use. The drug is a potent blood 
sohizontoe ide (1,64). 
1.7.2 Vector Control 
Vector control strategies for malaria- include 
either killing the Anopheles mosquitoes or preventing them 
from biting the human.s. The measures used to implement these 
strategies are listed below ; 
Use of insecticide.g : Adult mosquitoes can be killed by 
chemical insecticides like pyrethrum, chlorinated 
hydrocarbons, Dieldrin, Landrin, DDT etc., which are 
commercially available for spraying. 
Biological control : The mosquito at the larval stage 
can be destroyed by introducing larvivorous fish into the 
mosquito breeding waters. Certain bacteria such as Bacillus 
thurineiensis. viruses, protozoa and nematodes can be 
lethally pathogenic to the vector. 
Environmenta1 measures • The control of anopheline breeding 
grounds is implemented m all urban and rural areas either 
by eiiirdnating the mosquito breeding grounds or by the use 
of larvicidal oils on stagnant waters which contribute 
generously in the vector control for malaria (1,63). 
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Personal protection other than chemoprophvlaxis: These 
include methods to prevent the mosquitoes from biting the 
humans, and can be implemented by various means such as use 
of mosquito nets. Recent inventions of a mosquito net 
impregnated by an insecticide has successfully reduced the 
incidence of malaria in China. Screening of houses reduces 
the access of mosquitoes in the dwellings. The use of 
mosquito coils can reduce the chance of mosquito bites in a 
closed environment. Finally, mosquito repellents can be 
applied to the skin, clothes and bed nets to prevent bites. 
Synthetic repellents like Indalone, Rutgers 612, Dimethyl 
pthalate are now commercially available (1,63). 
1.7.3 Malaria Vaccines 
In 1957, WHO aimed at malaria eradication. The 
overwhelming success of malaria control program, which used 
DDT to kill mosquitoes and chloroquine for chemotherapy, was 
so very impressive that scientific research on developing 
malaria vaccines was neglected (1,65). 
However, unfortunately by the mid 70's the disease 
reappeared with a vengeance, largely because the malaris 
parasites had developed resistance against chloroquine, and 
also because the mosquito vector developed resistance to 
insecticides. 
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It is alarming that chloroquine and multiple 
resistant strains of E^ falciparum are spreading in most of 
the tropical countries of the world and it is equally 
alarming that new antimalarial drugs, especally for the 
prophylaxis are not likely to become available in the near 
future (66), and that no new insecticides superior to DDT 
and economically usable by poor malaria-endemic countries 
are on hand. With these problems in malaria control, great 
hopes have been placed on the development of effective 
malaria vaccines to supplement existing and future malaria 
control measures. 
Various methods of vaccination have been 
scrutinized and at present, there are three distinct malaria 
vaccines which are the focus of intense research. 
(1) Sporozoite vaccine : This seems to block the entry of 
sporozoites into the hepatocytes. This would eliminate 
the initiation of infection. Sporozoites are highly 
immunogenic as proved by the high level of 
antisporozoite antibodies seen in the indigenes of 
endemic areas. X-ray irradiated sporozoites were used 
in the initial trials in human volunteers and showed 
small protection (67). Subsequently, the protein 
covering the surface of the sporozoite known as the 
circumsporozoite protein (CSP) was identified as a 
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protective immunogen (68,69,70). The genes coding for 
CS protein consists of a repetitive sequence of 4 amino 
acids, viz asparagine, alanine, asparagine and proline 
(NANP). Trials on sporozoite vaccine which consisted of 
various repetition numbers of HAHP, adjuvanted in alum 
were carried out in 1987 and 1988 in human volunteers 
but did not yield satisfactory results. The problem 
mainly lies in the short duration of availability of 
sporozoites in the blood circulation of man, the time 
which does not suffice for specific antibody production 
and its action. The other problem lies in the species 
and strain variation which occurs and manifests in the 
antigenic variation in the CSP of the sporozoites and 
requires production of specific antibodies. The other 
problem lies in the species and strain specificity of 
the antisporozoite antibodies, and each fresh invasion 
by sporozoites needs a new compatible set of antibodies 
unless the infection is due to the invasion by 
homologous parasites, which is a rare condition in the 
endemic regions. 
2. Herozoite vaccine : This aims to block the invasion of 
merozoites into the erythrocytes. The stage of asexual 
schizogony is responsible for the morbidity and 
mortality in the disease. A merozoite vaccine would 
prevent the disease or significantly alleviate its 
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course of infection. A number of blood stage antigens 
have been identified as possible vaccine candidates 
(71,72,73,74). The first clinical trial was carried out 
in Columbia (75), although limited immunogenicity and 
protection have been demonstrated. The results of the 
trials have been encouraging in the sense that the 
first generation of synthetic and recombinant malaria 
vaccines have been found to be safe in the humans. The 
dissatisfactory results of the merozoite-vaccine is 
because of poor immunological response and protection, 
which are due to the inherent biological nature of the 
immunogen, synthetic and recombinant proteins (62). 
Besides these problems, the natural immunity developed 
towards blood stage antigen can be extrapolated to the 
artificial immunity induced through vaccination. The 
immunity is usually species and stage specific. The 
antibodies are generally protective unless challenged 
with the homologous strains of the parasite. 
Gametocvte vaccine : This is also known as the 
transmission-blocking vaccine; the vaccine is aimed to 
damage the sexual stages of the parasite life cycle. 
This vaccine would not prevent the infection or disease 
in the vaccine recepients but would block or allevtate 
the spread of the disease within the human population 
(62). Significant progress has been made in 
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identifying specific targets for antigamete immunity in 
a number of Plasmodia species including E_^  falciparum 
and E_^  vivax (76). This target is a 25 kD protein and 
the gene encoding one of the target proteins has been 
cloned (77). One reason malariologists favour a 
gametocyte vaccine is that sexual stage of the parasite 
is likely to be far less immunologically variable than 
others. Many of the sexual stage proteins currently 
being engineered are expressed only when the parasite 
enters the mosquito and not noticed by the immune 
system, they are less likely to vary. Antibodies raised 
against them would be useful when the blood is carried 
into the mosquito where the gametocyte antigens are 
expressed. This is expected to block fertilization 
hence blocking the completion of the life cycle of the 
Plasffiodiuffi (78). 
However, this vaccine is not without problems. Mendiz 
in 1987 (79) pointed out that low antigametocyte 
antibody titres in the mosquito blood meal may actually 
aid in bringing together the male and female 
gametocyte, increasing the chance of fertilization and 
making the disease more infectious. 
So far no effective vaccine is available against 
malaria. There are various problems associated with the 
development of a proper malarial vaccine which include the 
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complex life cycle of the malaria parasite and changes in 
both morphology and antigen expression; and also because 
each developmental form of the parasite contains a myriad of 
distinct, stage specific antigens. Moreover, only a small 
proportion of these antigens are capable of stimulating the 
production of specific antibodies and are stage and species 
specific and keep reshuffling its structure on the molecular 
level to evade the host's immune responses. 
The joint operation of T cells and immunoglobins 
A 
are essential for the consequential immunity to malaria, 
Adjuvants are required to carry the immunogenic subunits of 
the parasite, the latter being too small to induce host 
immune response independently. The ideal adjuvant must be a 
potent inducer of both humoral and cell mediated immune 
responses and be safe for use in humans. Alum has been used 
as an adjuvant in the malaria vaccines and has been found 
safe and effective in inducing humoral immunity but 
deficient in inducing cell mediated immunity (80,81). The 
necessity for safe and effective adjuvants and for 
incorporation of T cell epitopes in the vaccine molecules 
are additional major constraints towards subunits malaria 
vaccine developments. 
Designing a "cocktail" vaccine synthetically 
through recombined DMA technology, by combining a mixture of 
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sporozoites, merozoite and gametocyte defined antigens, each 
containing the conserved antigenic structures for eliciting 
T cell responses may circumvent some of the hurdles. 
The sporozoite and merozoite vaccines are meant to 
eliminate the initiation of infection and to significantly 
modify the severity and course of infection, respectively. 
However, the antigens associated in both the stages are 
capable of changing its protein coat in ways offering a 
bewildering variety of identities that enable some 
sporozoites evade the hosts immune surveillance. Even a 
"cocktail" of immunogenic proteins is unlikely to be 
effective, because the parasite may quickly evolve new 
variants in its proteins. 
Some malariologists still anticipate bright 
prospects for the development of effective malaria vaccines. 
Finally, if and when the malaria vaccine is available, it 
will serve as a supplement to the existing control measures. 
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1.8 AIMS AND OBJECTIVES 
The present study was aimed to assess and re-
evaluate the development of humoral immune responses during 
and after an attack of vivax mslaria. There is no doubt that 
the major current role of malaria antibody testing is in 
the epidemiological studies where malaria is or was endemic. 
In this context serology can provide useful complimentary 
information to that given by conventioal parasitological and 
clinical examination. The serological data can be considered 
as a combined indicator of point prevalence and recent 
period prevalence of the disease. The main practical aim of 
serology therefore is to first provide an index of 
prevalence of malaria in individuals living in malaria 
endemic areas prior to providing any assistance during and 
after mslaria control or eradication schemes (17). Apart 
from assessing the development of humoral immunity during an 
attack of vivax malaria, an attempt was also made in this 
study to monitor such responses over a considerable period 
of time following an attack. The aim was to come out with 
some sort of a follow up study, in order to determine the 
rate at which malarial antibodies decline under field 
conditions; that is under normal circumstances when one is 
exposed to reinfections and other natural stresses. 
The study was carried out in randomly selected 
patients in different age groups. Antibody monitoring was 
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carried out by means of indirect fluorescent antibody (IFA) 
test using fluorescein tagged antihuman antibodies. Some 
hand on information on the duration for which such malaria 
antibodies last was also considered necessary, for compiling 
8 baseline data before starting any vaccination trials - if 
and when that may be. The study could also be significant in 
gaining some insight on the sequential appearance of 
circulating malaria antibodies during various phases of the 
disease, including post recovery period. 
It would be quite in order to mention here that 
from a diagnostic point of view it is an established fact 
that malarial serology has little value in the diagnosis of 
acute malaria in the non-immune or semi-immune patients. 
However, estimation of antibody levels may have some 
diagnostic value in patients living in malarious areas with 
a history of fever but in whom the parasites have never been 
found due to the fact that blood films were taken at an 
inappropriate time, or after low-level antimalarial 
chemotherapy. In all such cases serology can be used to 
confirm or exclude malaria. It is especially important to 
detect E^ vivax in such circumstances as this infection has 
often led to relapses and radical treatment is neccessitated 
(17). 
The present investigations were therefore, 
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designed to study the g^ vivax antibody profiles in 
individuals from three different age groups listed below : 
1. Infants aged between 0 to 2 years with and without 
malaria. 
2. Children aged between 2 to 14 years with and without 
malaria. 
3. Adults aged between 15 to 56 years from both rural and 
urban areas with and without malaria. 
A follow up study from sera samples from 
individuals 15 to 90 days after recovery from vivax 
malaria, and from relapse cases of vivax malaria was carried 
out in the study groups comprising of children (2-12 years) 
and adults (15-56 years). 
MATERIALS AND METHODS 
4y 
2.1 MATERIALS 
Sera 
Blood samples for sera separation were collected 
randoinly from 63 inhabitants of both rural and urban areas 
in the Aligarh District of Uttar Pradesh (India). 
The samples were collected from three different 
age groups. Within each sample group, the sera were 
collected from persons with : (1) active slide-proven vivax 
malaria; (2) clinically suspected malaria (negative slide 
test results); (3) repeated (or relapsing) vivax malaria, 
(4) healthy individuals, and (5) individuals 1.5 to 90 days 
after attack of vivax malaria. In infants aged between 0 to 
2 years, samples were taken only from slide proven cases of 
vivax malaria, clinically suspected malaria cases and 
healthy controls. 
Data on whether or not chemotherapy was 
administered along with other details were collected from 
each patient on a pre-designed proforma as given in the 
Appendix. 
The various groups of subjects involved for sera 
collection are further categorised below : 
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AGE GROUPS/CASES TOTAL SAMPLES 
I. Infants Aged Between 0 to 2 Years 
1. Slide-Proven Vivax Malaria 4 
2. Clinically Suspected Vivax Malaria 5 
(Smear Negative) 
3. Healthy Controls 5 
II. Children Aged Between 2 to 14 Years 
1. Slide-Proven Vivax Malaria 8 
2. Clinically Suspected Vivax Malaria 4 
(Smear Negative) 
3. 15 to 90 Days After Recovery From 3 
Vivax Malaria 
4. Healthy Controls 4 
5. Relapsing Vivax Malaria 3 
III. Individuals Aged Between 15 to 56 Years 
1. Slide-Proven Vivax Malaria 8 
2. Clinically Suspected Vivax Malaria 5 
(Smear Negative) 
3. 15 to 90 Days After Recovery From 4 
Vivax Malaria 
4. Healthy Controls 5 
5. Relapsing Vivax Malaria 5 
Antigen 
P, vivax parasites from the infected blood slides 
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of vivax malaria patients, were used as antigen for IFA 
tests. 
E. falciparum parasites were also used as antigen 
and were obtained from the in vjtro cultures run in the 
laboratory. 
Glassware, Syringes and Plastic Vials 
The glassware used were from Pyrex and Company. 
Pre-sterilized, disposable plastic syringes and needles were 
obtained from Lycra (India) while plastic vials used for the 
storage of sera were bought from Basco Company (India). 
Stain 
Leishman stain was purchased in the powder form 
from BDH (England). 
Fixative 
Acetone used to fix the blood smears on the 
coverslips was obtained from Glaxo (India). 
Cheuicals 
Dihydrogen Sodium Phosphate (monobasic), Disodium 
Hydrogen Phosphate (dibasic) and Sodium Chloride used for 
buffer preparation were obtained form BDH (India), Sodium 
Azide used for preservation was bought from Indian Drugs & 
^' JU 
Pharmaceuticals Ltd. Methanol was obtained from Merck and 
Company Ltd. 
Anticoagulant 
Acid Citrate Dextrose was obtained from the Blood 
Bank, J.N. Medical College, A.M.U., Aligarh. 
Medium 
Waymouth's MB 752/1 medium was obtained from the 
Grand Island Biological Company (USA). 
Conjugate 
Fluorescein isothiocyanate (FITC) labelled anti-
human IgG, IgM and IgA were obtained from Immunodiagnostics 
Ltd. (India). 
Slides and Coverslips 
Both slides and coverslips were obtained from Blue 
Star : Polar Industrial Corporation (India). 
2.2 METHODS 
2.2.1 Serun Collection 
Between 3 to 5 ml of venous blood from the 
patients was collected in plain glass vials and left 
overnight in the refrigerator at 4°C and serum was separated 
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from the clot, subsequently. The serum was stored in 2 ml 
screw-capped plastic vials after labelling at -20''C till 
needed . 
2.2.2 Antigen Preparation 
P• falciparum antigen was prepared from infected 
red blood cells obtained from in. vitro cultured parasites. 
IXL vitro cultures were made in the laboratory by fellow 
researchers as per modified method of Siddiqui (82). 
P. vivax antigen was also used in this study. The 
parasites from the blood of slide-proven vivax malaria 
patients with high parasitemia (of about 0.8 to 1%) 
containing most parasites at the schizont stage were used as 
a source of antigen for serum antibody detection in IFA 
tests. 
In some cases^venous blood from slide-proven vivax 
malaria patients with high parasitemia containing parasites 
at the trophozoite stage was collected in vials with 
anticoagulant. The infected blood samples were constituted 
to a 1:1 ratio with Waymouth's MB 752/1 medium ((83) and 
incubated at 37°C for 1-8 hours, while ordinary microscopy 
was done from time to time to check the development of 
initial trophozoite stages into mature trophozoites and 
schizonts. Parasites following their short term incubation 
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and maturity were eventually smeared on the coverslips at 
the appropriate time. 
All smears were fixed in acetone for 5 to 10 
minutes. The fixed coverslips were then wrapped in tissue 
paper and packed in airtight container in small batches and 
stored at -20°C till needed. 
2.2.3 Microscopy 
Ordinary light microscopy was performed on the 
blood smears of patients with primary patent vivax malaria, 
in order to further confirm the disease and determine the 
infecting species of the Plasmodium prior to serum 
collection and, of course, antigen preparation. 
Leishman stain was used to stain the thin blood 
films. The detailed staining technique is given below: 
Preparation of Leishman Stain 
The stain used was in the form of powder. The 
strength of the solution used for staining was 0.15 per cent 
of the stain in methanol. An 0.15 gram sample of the stain 
was dissolved in 100 ml. of acetone-free pure methanol for 
obtaining the above stain concentration. The materials 
required for preparation were: 
(i) ground-glass stoppered bottle of 150 ml. capacity 
(ii> 100 ml. graduated glass cylinder 
(iii) glass inortar and pestle 
All the articles were thoroughly cleared and rinsed with 
methanol before use. A 100 ml. methanol was first measured 
in the graduated measuring cylinder. The weighed amount 
(0.15 g) of Leishman powder was placed in the mortar and 
ground into a paste by adding methanol in small quantities 
(about 2 ml. each time). The dissolved stain was carefully 
decanted off from time to time into a glass-stoppered 
bottle. The individual stain was grinded again with methanol 
till no residue was left and the whole methanol had been 
used up. The stoppered-glass bottle with the stain was kept 
in an incubator at 37°C for 24 hours while being filtered 
after which time it was ready for use (11). 
Staining Procedure 
(i) Leishman's stain was poured from a drop bottle by 
means of pipette over the dried film and allowed 
to remain for 30 seconds. 
(ii) The stain was diluted with twice its volume of 
distilled water which was enough to be 
neutralised, or left it slightly alkaline (pH 
7.0 to 7.2). It was later covered to prevent it 
from drying. 
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(iii) The diluted stain was allowed to remain on the 
slide for 10 to 15 minutes. 
(iv) The slide was held under an open tap and the stain 
flushed by gentle flow of water. The reverse side 
of the slide was cleared by rubbing it well with 
wet, squeezed cotton wool. 
(v) The slide was kept in an upright position (film-
slide inwards) to drain and dry. 
(vi) The dried stained film was examined in the 
oil immersion objective of the microscope. 
2.2.4 Buffer Preparation 
0.1 M Phosphate Buffered Ssline (PBS) at pH 7.2 
was the buffer used in this study. Details of its 
preparation is as follow : 
Phosphate buffered saline was prepared by 
incorporating Dihydrogen Sodium Phosphate, Disodium Hydrogen 
Phosphate and Sodium Chloride. The solution was made at 0,01 
molarity, pH 7.2. 
The weight of the chemicals involved were 
calculated by substitution in the following formula; 
molarity x molecular weight x volume (ml.) 
weight (g) - - - "- -
1000 
S7 
Thus, the weight of the components in 1000 ml solution was 
calculated as: 
1. Dihydrogen Sodium Phosphate (monobasic): 
0.01 X 156.01 X 1000 
weight (g) = - =1.56 
1000 
2. Dihydrogen Hydrogen Phosphate (dibasic): 
0.01 X 178.16 X 1000 
weight (g) = - - =1.78 
1000 
3. Sodium Chloride : 
0.15 X 58.45 X 1000 
weight (g) = - - - - = 8.77 g 
1000 
The final volume was made to 1000 ml in double 
distilled water and the pH adjusted to 7.2. A pinch of 
Sodium Azide was added to the buffer for preservation and 
the buffer stored at 4°C in the refrigerator until needed. 
Indirect Fluorescent Antibody (IFA) Test Technique 
The procedure outlined in the World Health 
Organization Memorandum (1974) was used with a few 
modifications (84). 
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Antisera and antigen coverslips were taken out 
from storage, and raised to room temperature for 20 to 30 
minutes. Antigen coverslips were washed for 10 minutes in 
distilled water by slowly agitaing them in a Petri dish 
containing distilled water. After the coverslips were 
washed, they were removed from the bath, and the excess 
fluid was removed by careful blotting. The antigen 
coverslips were labelled and placed in moist chambers 
prepared by lining Petri dishes with wet filter paper. 
Antisera to be tested were diluted with PBS (pH 
7.2) in two-fold steps, starting at a dilution of 1:10. 
About 0.05 ml. of each dilution was dispensed on labelled 
antigen smears. The chamber was covered and incubated at 
SyC for 30 minutes. 
After incubation, excess serura was removed from 
each coverslip with a gentle stream of PBS followed by 
gently agitating the coverslip in a Petri dish containing 
PBS for 5 minutes, discarding and replacing it with fresh 
PBS to complete a series of 3 consecutive washings. The 
coverslips were then removed from the wash and replaced in 
the moist chamber. 
The fluorescein isothiocyanate conjugated (FITC) 
antihuman IgG, FITC antihuman IgM and FITC antihuman IgA 
diluted to an optimal strength in PBS were applied to 
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antigen areas on individual coverslips with the same serum 
dilution and allowed to react for 20 to 30 minutes at 37°C. 
Excess conjugate was removed by a gentle saline stream 
followed by three serial washings in PBS of 5 minutes each, 
and then blotted dry with filter paper. The slides were then 
mounted with the smeared coverslips using buffered glycerol. 
The edges of the coverslips were sealed with finger nail 
varnish. 
Two controls, a negative control made by placing a 
drop of PBS on one slide and a positive control made by 
placing a drop of a known positive antimalarial serum on the 
other were also made for examination and comparison. 
The stained coverslips were examined immediately 
under the fluorescent microscope (Olympus Co. Ltd., Japan) 
equipped with Exciter Filter UGI and Barrier Filter L420, 
and a D.C. 200-watt high pressure mercury burner employed as 
the light source. The last serum dilution yielding 
detectable fluorescence was considered as the end-point and 
the titre was expressed as a reciprocal of that dilution i.e 
1:20, 1:40 and so on. 
RESULTS 
6 LI 
Antigen Preparation 
Continuous in vitro cultures of E_^  falciparum 
carried out in our laboratories by fellow researchers were 
used for obtaining the antigen for indirect fluorescent 
antibody (IFA) test (2). The in vitro cultures attained a 
peak parasitemia level of 10% after the seventh week, 
yielding a population of parasites consistng mainly of ring 
forms and trophozoites. Schizonts were found to constitute 
only 10-25% of the population. Gametocytes were only rarely 
observed. Such a parasite yield was optimum for preparing 
antigen smears on coverslips that could serve to carry out 
the IFA tests. 
P. vivax antigen was either obtained directly from 
infected patients with most parasites in the mature 
trophozoite and schizont stages and having a parasitemia 
level ranging between 0.8-1%. Alternatively, the antigen 
used was prepared from E_^  vivax infected patients' blood 
with similar parasitemic levels. Few samples of infected 
blood with early erythrocytic stages of E_^  vivax were 
incubated for short term cultures in vials containing 
Waymouth's MB 752/1 medium and anticoagulant(Acid Citrate 
Dextrose) at dl'C. Such samples were found to yield a 
parasite population with a majority of the immature stages 
having developed into late trophozoite and schizont stages 
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within 4 to 8 hours. Thin blood smears suitable for the IFA 
tests were made, subsequently. 
Indirect Fluorescent Antibody (IFA) Test 
The IFA test was performed according to a modified 
procedure outlined by the World Health Organization 
Memorandum (87). The working dilution of the fluorescein 
isothiocyanate conjugated (FITC) antihuman IgG, IgM and IgA 
was determined and a dilution of 1:20 was found optimal for 
use in the IFA test. Immune sera samples and acetone-fixed 
antigen smears on coverslips when reacted with FITC 
antihuman antibodies produced a greenish fluorescence under 
ultravoilet light. An illustration of this is presented in 
Figure 1. 
Control slides smeared with non-immune serum did 
not show any fluorescence, while the positive control slides 
made by using a known positive antimalarial serum in the IFA 
tests produced detectable fluorescence. 
Tables 1(1), 1(2) and 1(3) show IFA test results 
in infants aged between 0 to 2 years with slide-proven vivax 
malaria, clinically suspected vivax malaria and in healthy 
controls, respectively. 
All sera obtained from infants (0-2 years) with 
slide-proven vivax malaria produced fluorescence at 
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Figure 1: Fluorescence Produced in the Indirect 
Fluorescent Antibody (IFA) Test on Acetone - Fixed 
Blood Film Infected with P. vivax (x 1000) 
e.ji 
dilutions of 1:10 and 1:20 when reacted with FITC antihuman 
IgG, indicating the presence of malaria specific IgG in the 
test sera (Table 1(1)). However only 25% test sera produced 
fluorescence at a dilution of 1:40. At the next consecutive 
dilutions of 1:80 and 1:160 no fluorescence with FITC 
antihuman IgG was detected in any test serum. Only 50% test 
sera produced fluorescence, thus indicating the presence of 
malaria specific IgM at a dilution of 1:10 and 1:20 when 
reacted with FITC antihuman IgM, while only 25% samples gave 
positive results for the presence of malaria specific IgM at 
a serum dilution of 1:40. Ho fluorescence was detected in 
dilutions of 1:80 and above, IgA against malaria was also 
not detected in any serum sample from the infants' (0-2 
years) group having a slide-proven vivax malaria. 
IFA antibody titres recorded in infants (0-2 
years) with clinically suspected vivax malaria, having 
negative results of peripheral blood smear microscopy are 
provided in Table 1(2). A total of five sera samples were 
studied in this group. Malaria specific IgG was detected in 
40% samples at a dilution value of 1:10, reducing to 20% at 
a serum dilution of 1:20. Ho antibodies were detected at 
the higher dilutions of 1:40, 1:80 and 1:160. Malaria 
specific IgM was detected in 80% sera samples at a dilution 
of 1:10 and decreased to 60% at a serum dilution of 1:20, 
and further dropped to only 20% at a serum dilution of 1:40. 
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No malaria specific IgM was detected in seruiri dilution of 
1:80 and above. IgA against malaria was detected in 20% test 
sera at a dilution of 1:10; higher dilutions of 1:20 and 
1:40 yielded negative results for the presence of malaria 
specific IgA. 
Healthy controls in the infants' (0-2 years) group 
were also tested for the presence of malarial antibodies 
using the IFA test. Results of the study are indicated in 
Table 1(3). Highest level of antimalarial IgG was observed 
in 60% healthy infants at a serum dilution of 1:10. The 
levels decreased in the higher dilutions of the test sera 
with only 20% healthy infants showing the presence of 
specific IgG for malaria at 1:20 and 1:40 serum dilutions. 
No IgG against malaria was detected when sera were diluted 
to 1:80 and 1:160. 
Antimalarial IgM was detected in 60% of the tested 
healthy infants at a serum dilution of 1:10. At a further 
serum dilution of 1:20 only 20% healthy infants sera tested 
were found to have malaria specific IgM. All other higher 
dilutions of 1:40, 1:80 and 1:160 gave negative results. 
Malaria specific IgA could not be detected in any test sera 
of this group. 
Table 1(1) 
IFA TEST TITRES IM IMFAMTS AGED BETWEEN 0 TO 2 YEARS 
(Slide-Proven Vivax Malaria Cases) 
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IFA test 
titres 
Serum Antibodies in IFA 
IgG IgM IgA 
1:10 
1:20 
1:40 
1:80 
1:160 
4 (100%) 
4 (100%) 
1 (25%) 
0 (0%) 
0 (0%) 
2 (50%) 
2 (50%) 
1 (25%) 
0 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
Table I (2) 
IFA TEST TITRES IN INFANTS AGED BETWEEN 0 TO 2 YEARS 
(Clinically Suspected for Malaria; Slide Negative Cases) 
IFA test 
titres IgG 
Serum Antibodies in IFA 
IgM IgA 
n = 0 
1: 10 
1:20 
1:40 
1:80 
1:160 
2 (40%) 
1 (20%) 
0 (0%) 
0 (0%) 
0 (0%) 
4 (80%) 
3 (60%) 
1 (20%) 
0 (0%) 
0 (0%) 
1 (20%) 
0 (0%) 
0 (0%) 
Number of Samples (n) 
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Table I (3) 
IFA TEST TITRES IN INFANTS AGED BETWEEN 0 TO 2 YEARS 
(Healthy Controls) 
IFA test 
titres 
1:10 
n = 6 
1:20 
1:40 
1:80 
1: 160 
I Serum 
IgG 
3 (60%) 
1 (20%) 
1 (20%) 
0 (0%) 
0 (0%) 
Ant ibodies 
IgH 
3 
1 
0 
0 
0 
(60%) 
(20%) 
(0%) 
(0%) 
(0%) 
in IFA 
IgA 
0 (0%) 
0 (0%) 
0 (0%) 
-
-
* - Number of Samples (n) 
67 
IFA test results in children aged between 2-14 
years are provided in Tables 11(1), II(2>, 11(3), 11(4) and 
11(5). Children (2-14 years) with slide-proven vivax malaria 
were found to have higher levels of antimalarial IgM as 
compared to antimalarial IgG (Table 11(1)). One hundred 
percent samples were found positive for the presence of 
antimalarial IgM in all serum dilutions of 1:10, 1:20, 1:40, 
1:80 and 1:160, while malaria specific IgG was found in all 
sera at 1:10 and 1:20 dilutions only. Subsequent dilutions 
of 1:40 and 1:80 showed 62.5% sample positivity indicating 
for presence of IgG. At a further at a dilution of 1:160 
about 25% sera indicated the presence of specific IgG 
dropping down to only 12.5% in sera samples at dilutions of 
1:320 and 1:640. No IgG was detectable at a dilution of 
1:1280. 
IgM titres in this group of children with slide-
proven vivax malaria fell from 100% samples showing the 
presence of antimalarial IgM at dilutions upto 1:160 to only 
67.5% sample positivity at a serum dilution of 1:320. This 
further declined to only 25% sample positivity for the 
presence of IgM at a dilution of 1:640. Further serum 
dilutions gave negative results. 
Malaria specific IgA was detected in 12.5% test 
samples at a dilution of 1:10. Further dilutions gave 
By 
negative results for IgA. 
Children with clinical symptoms of vivax malaria 
but in whom the blood smear microscopy detected no malaria 
parasites were found to have malaria specific IgG in all the 
four sera samples studied at a dilution of 1:10 (Table 
11(2)). At a serum dilution of 1:20, the percentage sample 
positivity dropped to only 25%. The sample positivity rose 
unexpectedly to 50% at the next higher serum dilutions of 
1:40 and 1:80; this was probably due to some experimental 
error. No IgG was detected in serum dilutions above 1:80. 
IgH in this group of children (Table 11(2)) was 
found in all cases (100%) at a serum dilution of 1:10, and 
at a further dilution of 1:20 and 1:40, only 75% test sera 
indicated the presence of specific IgM, declining to only 
50% at a dilution of 1:80. Only 25% samples showed the 
presence of IgM by the IFA test at a dilution of 1:160 and 
further dilutions of 1:320 and 1:640 produced negative 
results. 
A quarter portion of sera of children with 
clinically suspected malaria had indicated the presence of 
malaria specific IgA at dilutions of 1:10 and 1:20, further 
dilutions of 1:40, 1:80 and 1:160 gave negative results. 
Table 11(3) summarises the IFA test results on 
three sera samples from children (2-14 years) obtained 15 to 
ti'd 
90 days after recovery froiri a confirmed attack of vivax 
malaria. IgG levels were highest as compared to the levels 
of IgH and IgA showing a positivity in 100% test sera in all 
dilutions of 1:10, 1:20, 1:40. 1:80, 1:160 and 1:320. Later, 
it fell to 66.6% sample positivity at a serum dilution of 
1:640 and declined further to only 33.3% samples showing the 
presence of malaria specific IgG at a serum dilution of 
1:1280. 
Presence of IgM was indicated in 100% test sera at 
dilutions of 1:10 and 1:20. These values later declined to 
66.6% sample positivity at a dilution of 1:40 and only 33.3% 
sera were positive at 1:80 dilution. No antibody was 
detectable in further dilutions of 1:160 and 1:1280. IgA 
against malaria was not found in any test sera. 
Table 11(4) shows the IFA test results in sera 
samples of apparently healthy children (2-14 years). Only 
50% cases were found to have malaria specific IgG at a 
dilution of 1:10, thereafter further dilutions gave negative 
results for the presence of malaria specific IgG. On the 
other hand, IgM levels were comparatively higher with 100% 
samples showing fluorescence at dilution of 1:10 and 1:20. 
Only 25% test sera showed fluorescence at 1:40, 1:80 and 
1:160 dilutions. No fluorescence was recorded in serum 
dilution of above 1:160. IgA was found in low amounts in 
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only 25% test sera at a dilution of 1:10 and 1:20, 
subsequent higher dilutions gave negative results. 
Relapses due to E_^  vivax infections lead to a 
rapid rise in the IgG titres (42). A total of three sera 
samples from children (2-14 years) having slide positive 
vivax malaria and presenting with a history of previous 
attacks of vivax malaria 3 to 6 months before the prevailing 
P • vivax infection were tested for antimalarial antibody 
levels using the IFA test. The results are summarized in 
Table 11(5). All the three test sera showed fluorescence at 
a dilution of 1:10 and 1:20 when reacted with FITC antihuman 
IgG. At dilutions of 1:40, 1:80, 1:160, 1:320 and 1:640 only 
one out of the three (33.3%) test sera gave positive 
results. The next higher dilution of 1:1280 gave negative 
results. 
IgH was detected more significantly in all the 
test sera giving a positive result for the presence of 
antimalarial IgM at serum dilutions of 1:10 and 1:20. Two 
out of the three test sera indicated IgM antibodies in 
dilutions of 1:40, 1:80 and 1:180. Negative results were 
recorded in dilution of 1:320 and above for the presence of 
malaria specific IgM. 
Ho samples in this group were tested for the 
presence of antimalarial IgA. 
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Table II (1) 
IFA TEST TITRES IN CHILDREN AGED BETWEEN 2 TO 14 YEARS 
(Slide-Proven Vivax Malaria Cases) 
IFA test 
titres 
* 1^10 
*n ^ 8 
1:20 
1:40 
1:80 
1:180 
1: 320 
1:640 
1:1280 
Serum 
1 IgG 
8 
8 
5 
5 
2 
1 
0 
0 
(100%) 
(100%) 
(62.5%) 
(62.5%) 
(25%) 
(12.5%) 
(0%) 
(0%) 
Ant ibodies in 
IgM 
8 
8 
8 
8 
8 
7 
2 
0 
(100%) 
(100%) 
(100%) 
(100%) 
(100%) 
(87.5%) 
(25%) 
(0%) 
IFA 
IgA 
1 
0 
0 
0 
0 
-
-
-
(12.5%) 
(0%) 
(0%) 
(0%) 
(0%) 
Table II (2) 
IFA TEST TITRES IN CHILDREN AGED BETWEEN 2 TO 14 YEARS 
(Clinically Suspected for Malaria; Slide Negative Cases) 
IFA test 
titres IgG 
Serum Antibodies in IFA 
IgM IgA 
n = 4 
1:10 
1:20 
1:40 
1:80 
1:160 
1:320 
1:640 
1:1280 
* - Number of Samples (n) 
4 (100%) 
1 (25%) 
2 (50%) 
2 (50%) 
0 (0%) 
0 (0%) 
4 (100%) 
3 ( 75%) 
3 (75%) 
2 (50%) 
1 (25%) 
0 (0%) 
0 (0%) 
1 (25%) 
1 (25%) 
0 (0%) 
0 (0%) 
0 (0%) 
Table II (3) 
IFA TEST TITRES IH CHILDREN AGED BETWEEN 2 TO 14 YEARS 
(Post Recovery Cases) 
IFA test 
titres 
1:10 
*n = 3 1:20 
1:40 
1:80 
1: 160 
1:320 
1:640 
1:1280 1 
Serum 
IgG 
3 
3 
3 
3 
3 
3 
2 
1 
(100%) 
(100%) 
(100%) 
(100%) 
(100%) 
(100%) 
(66.6%) 
(33.3%) 
Ant ibodies in 
IgM 
3 
3 
2 
1 
0 
0 
0 
0 
(100%) 
(100%) 
(66.6%) 
(33.3%) 
(0%) 
(0%) 
(0%) 
(0%) 
IFA 
IgA 
0 (0%) 
0 (0%) 
0 (0%) 
-
-
-
-
-
Table II (4) 
IFA TEST TITRES IN CHILDREN AGED BETWEEN 2 TO 14 YEARS 
(Healthy Controls) 
IFA test 
titres 
n = 4 
1:20 
1:40 
1:80 
1:160 
1:320 
1:640 
1:1280 1 
IgG 
2 (50%) 
0 (0%) 
0 (0%) 
0 (0%) 
-
-
-
-
Serum Ant ibodies in 
IgM 
4 
4 
1 
1 
1 
0 
0 
0 
(100%) 
(100%) 
(25%) 
(25%) 
(25%) 
(0%) 
(0%) 
(0%) 
IFA 
IgA 
1 
1 
0 
0 
0 
-
-
-
(25%) 
(25%) 
(0%) 
(0%) 
(0%) 
* - Number of Samples (n) 
73 
Table II (5) 
IFA TEST TITRES IH CHILDREN AGED BETWEEN 2 TO 14 YEARS 
(Relapse/Reinfection Cases) 
IFA test 
titres 
1:10 
1:20 
n - J 
1:40 
1:80 
1: 160 
1:320 
1:640 1 
1:1280 1 
Serum 
1 IgG 
3 
3 
1 
1 
1 
1 
1 
0 
(100%) 
(100%) 
(33.3%) 
(33.3%) 
(33.3%) 
(33.3%) 
(33.3%) 
(0%) 
Ant ibodies in 
IgH 
3 
3 
2 
2 
2 
0 
0 
0 
(100%) 
(100%) 
(66.6%) 
(66.6%) 
(66.6%) 
(0%) 
(0%) 
(0%) 
IFA 
IgA 
-
-
-
-
-
-
-
-
Number of Samples (n) 
74 
Sera from adults aged between 15 to 56 years were 
tested, the results of which are provided in Tables III(l) 
to 111(5). 
A total of eight adults (15-56 years) with slide-
proven vivax malaria volunteered to donate blood for IFA 
studies. In such IFA tests (Table III (1)), all the samples 
showed the presence of IgG when sera were diluted to titres 
of 1:10, 1:20 and 1:40. Six out of the eight samples (75%) 
gave positive results for antimalarial IgG when diluted to 
1:80, while only half of the samples indicated the presence 
of IgG at 1:160 dilution. At a serum dilution of 1:320, only 
25% samples showed the presence of malaria specific IgG. In 
dilutions of 1:640 and above no malaria specific IgG was 
detected. 
IgM was demonstrated in all the eight sera samples 
at dilutions of 1:10 to 1:80. About 25% samples showed 
antimalarial IgM antibodies at a dilution of 1:160, while at 
dilutions of 1:320 and 1;640 only one out of eight samples 
showed fluorescence. No fluorescence was recorded at a next 
higher dilution of 1:1280, indicating the absence of 
antimalarial IgM in the test sera. 
IgA was present in 25% samples at dilutions of 
1:10 and 1:20. Ho IgA was detected at higher sera dilutions 
of 1:40, 1:80 and 1:160. 
Sera from adults in whom malaria was diagnosed on 
the basis of clinical symptoms (slide tests detected no 
parasites in the peripheral blood) were obtained for IFA 
test. A total of 5 samples were tested. The results of the 
test are shown in Table 111(2). 
IFA test detected malaria specific IgG in all the 
five samples at 1:10 dilution. Further dilutions of 1:20, 
1:40 and 1:80 were found positive for IgG in only 40% 
samples. At the next higher serum dilution of 1:160 only 20% 
samples produced fluorescence. No fluorescence was seen m 
dilutions of 1:320, 1;640 and 1:1280 indicating the absence 
of malaria specific IgG at these dilutions. 
IgM was detected in all sera diluted to 1:10 and 
1:20, the levels declined as indicated at a dilution of 1:40 
and 1:80 where only 60% samples produced fluorescence. At 
dilutions 1:160 and 1:320 the antimalarial IgM antibodies 
were detectable in only 20% samples. Further dilutions 
yielded negative results. 
Antimalarial IgA was detected only at a dilution 
of 1:10, in 20% sera samples, subsequently higher dilutions 
of the test sera gave negative results. 
IFA studies were also carried out on 4 sera from 
adults obtained 30 to 90 days after the recovery from an 
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attack of slide-proven malaria (Table 111(3)). High 
antimalarial IgG levels were found in this group of adults 
with 100% samples indicating the presence of malaria 
specific IgG in all dilutions starting from 1:10 to 1:160. 
The last serum dilution indicating the presence of IgG was 
1:640. 
IgM levels were comparatively low with only 1:10 
and 1:20 dilutions giving positive results in 100% samples. 
At a dilution of 1:40 and 1:80 only 25% samples remained 
positive for the presence of IgM. Subsequent dilutions of 
1:160, 1:320 and 1:640 yielded negative results. Ho samples 
were run for the detection of malaria specific IgA. 
Sera from healthy adults (15-56 years) used as 
controls showed 80% sample positivity at a dilution of 1:10 
and 1:20. But only one out of a total of five sera samples 
(20%) produced fluorescence at subsequent dilutions, 
reaching an end-point at a dilution of 1:160 (Table 111(4)). 
Compared to 100% positive sera at 1:10 and 1:20 
dilutions IgM values were somewhat lower to only 40% 
positive samples at 1:40 and 1:80 dilutions in the healthy 
control group of adults. No fluorescence was found in the 
higher dilutions at 1:160 and 1:320. 
IgA was found in 40% samples from the healthy 
adults' group at 1:10 dilutions and in only 20% samples at 
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1:20 dilutions. Ho fluorescence was found at dilutions of 
1:40 and 1:80. 
Sera from relapse oases in adults were taken on 
the same criterion as for the relapse patients in 2 to 14 
years age group. 
Specific IgG against Plasmodium was detectable in 
all the five test sera at dilutions of 1:10 and 1:20 (Table 
111(5)). At dilutions of 1:40, 1:80 and 1:160, 80% samples 
indicated the presence of antimalarial IgG, declining to 
only 50% positive samples at a serum dilution of 1:320. Ho 
antimalarial IgG was detected at a dilution of 1:640. At a 
higher dilution of 1:1280. Only one sample out of the five 
test sera produced fluorescence. 
Antimalarial IgM was found in all the five test 
sera at dilutions of 1:10, 1:20 and 1:40, dropping sharply 
to only one test serum yielding fluorescence at a dilution 
of 1:80. Subsequent higher dilutions of 1:160, 1:320 and 
1:640 yielded negative results for the presence of malaria 
specific IgM. 
IgA against malaria was not tested in any sera 
sample of this group. 
Table III (1) 
IFA TEST TITRES IN ADULTS AGED BETWEEN 15 TO 56 YEARS 
(Slide-Proven Vivax Malaria Cases) 
78 
^ 
n " 
IFA test 
titres 
1:10 
- 8 
1:20 
1:40 
1:80 
1:160 
1:320 ! 
1:640 ! 
1:1280 I 
Serum 
1 IgG 
1 8 
8 
8 
8 
4 
2 
0 
0 
(100%) 
(100%) 
(100%) 
(75%) 
(50%) 
(25%) 
(0%) 
(0% ) 
Ant ibodies in 
IgM 
8 
8 
8 
8 
2 
1 
1 
0 
(100%) 
( 100%) 
(100%) 
(100%) 
(25%) 
(12.5%) 
(12.5%) 
(0%) 
IFA 
IgA 
2 (25%) 
2 (25%) 
0 (0%) 
0 (0%) 
0 (0%) 
-
-
-
Table III (2) 
IFA TEST TITRES IN ADULTS AGED BETWEEN 15 TO 56 YEARS 
(Clinically Suspected for Malaria; Slide Negative Cases) 
IFA test 
titres 
^ 1:10 
n = 5 
1:20 
1:40 
1:80 
1:160 1 
1:320 1 
1:640 1 
1:1280 ; 
Serum 
1 IgG 
1 5 
2 
2 
2 
1 
0 
0 
0 
(100%) 
(40%) 
(40%) 
(40%) 
(20%) 
(0%) 
(0%) 
(0%) 
Ant ibodies in IFA 
IgM 
5 
5 
3 
3 
1 
1 
0 
0 
(100%) 
(100%) 
(60%) 
(60%) 
(20%) 
( 20%) 
(0%) 
(0%) 
IgA 
1 (20%) 
0 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
-
-
-
* - Number of Samples (n) 
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Table III (3) 
IFA TEST TITRES IM ADULTS AGED BETWEEN 15 TO 56 YEARS 
(Post Recovery Cases) 
IFA test 
titres 
1:10 
n = 4 1:20 
1:40 
1:80 
1:160 
1:320 ; 
1:640 1 
1:1280 1 
Serum 
1 IgG 
4 
4 
4 
4 
4 
1 
2 
0 
(100%) 
(100%) 
(100%) 
(100%) 
(100%) 
(25%) 
(50%) 
(0%) 
Ant ibodies 
IgM 
4 
4 
1 
1 
0 
0 
0 
-
(100%) 
(100%) 
(25%) 
(25%) 
(0%) 
(0%) 
(0%) 
in IFA 
IgA 
-
-
-
-
-
-
-
-
Table III (4) 
IFA TEST TITRES IN ADULTS AGED BETWEEN 15 TO 56 YEARS 
(Healthy Controls) 
IFA test 
titres 
1:10 
* n = 5 1:20 
1:40 
1:80 
1:160 
1:320 ! 
1:640 i 
1:1280 i 
Seruiri 
1 IgG 
4 
4 
1 
1 
1 
0 
0 
-
(80%) 
(80%) 
(20%) 
(20%) 
(20%) 
(0%) 
(0%) 
Ant ibodies 
IgM 
5 
5 
2 
2 
0 
0 
-
-
(100%) 
(100%) 
(40%) 
(40%) 
(0%) 
(0%) 
in IFA 
IgA 
2 (40%) 
1 (20%) 
0 (0%) 
0 (0%) 
-
-
-
-
* - Number of Samples (n) 
80 
Table III (5) 
IFA TEST TITRES IH ADULTS AGED BETWEEN 15 TO 56 YEARS 
(Relapse/Reinfection Cases) 
IFA test 
titres 
1:10 
1:20 
n = 5 
1:40 
1:80 
1:160 , 
1:320 1 
1:640 1 
1:1280 1 
Serum 
! IgG 
5 
5 
4 
4 
4 
2 
0 
1 
(100%) 
(100%) 
(80%) 
(80%) 
(80%) 
(40%) 
(0%) 
(20%) 
Ant ibodies in IFA 
IgM IgA 
5 
5 
5 
1 
0 
0 
0 
-
(100%) 
(100%) 
(100%) 
(20%) 
(0%) 
(0%) 
(0%) 
-
Number of Samples (n) 
81 
Sera samples were also collected froiri six patients 
ranging from 2 1/2 to 5 years of age in whom E.. vivax was 
reported on smeai; microscopy but were found slide negative 
after antimalarial chemotherapy. In these cases, the results 
on serum dilutions which reacted with FITC antihuman IgG and 
IgM to produce detectable fluorescence are shown in Table IV 
for each of the 6 patients. 
In all the cases, the end serum titre indicating 
the presence of IgM was always higher compared to the last 
dilution at which IgG was detectable. For example, in one 
patient aged 2 1/2 years following chemotherapy the 
antimalarial IgM was detectable at a dilution upto 1:320, 
while IgG was detectable only upto 1:40 dilution. These 
results are further illustrated in Figure 2. 
Table IV 
Antinalarial Antibody Profiles in Slide-Proven Vivax 
Malaria Cases After Adainistration of Chemotherapy 
Age (Years) 
2 1/2 
24 
27 
50 
8 
14 
1 IgG 
1:40 
1:80 
1:40 
1:80 
1:40 
1:80 ; 
1 IgM 
1:320 
1: 160 
1: 160 
1:320 
1: 160 
1:160 
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Figure 2: Profiles of malar ia 
specific IgG &c IgM levels in 6 
vivax inalaria cases after I r e a t m e n i 
Reciprocal IFA tires 
IgG CZJ IgM 
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Figure 3: Profiles of malar ia specific 
IgG li tres in healthy individuals of 
Aligarh District increasing with age. 
Reciprocal IFA litres 
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DISCUSSION AND CONCLUSION 
4.1 DISCUSSION 
Repeated malaria infection in individuals living 
in malaria endemic and particularly in holoendemic areas 
results in the development of immunity against pathogenic 
asexual stages of Plasmodium parasites; such immunity 
reduces parasite load and severity of the clinical illness. 
During malaria infection, there is a marked increase in 
serum immunoglobulin levels, part of which is specific to 
malaria parasites. It has already been established that 
specific malarial antibody activity can be demonstrated in 
IgG, IgM and IgA fractions of the immune sera (56,57) and 
IgG is predominant in established infections (53). 
In order to investigate the natural response to 
erythrocytic asexual stage antigens, the present study 
sought to test sera samples for the presence of malaria 
specific IgG and IgM antibodies (in a few cases malaria 
specific IgA was also screened) in different age groups 
ranging from 0 to 56 years in the inhabitants of Aligarh 
District, which is known to be endemic for malaria (85). 
The method employed for the antibody detection in 
this investigation was the indirect fluorescent antibody 
(IFA) test. IFA test has been used extensively and at the 
present time it is considered as the test of choice for 
determination of malarial antibody (17,34). IFA test detects 
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antibody very soon after the blood is invaded and the 
percentage of false negatives is lower than with other 
tests. This may be due to the fact that whole parasite is 
used as an antigen in IFA test (42). 
Results froiri this study indicate that people 
repeatedly exposed to natural infection by E_^  vivax in the 
Aligarh District show the presence of malaria specific 
antibodies of the IgG and IgM fractions , (In some cases IgA 
was also found on screening). 
Infants between 0-2 years of age were found to 
have low levels of IgG against Plasmodium, irrespective of 
whether they had a positive slide test or not. 
It was found that a cross- sectional serological 
survey could provide an index of the overall level of 
malarial experience by a community (86,87,88). The results 
of these studies were in agreement showing that new-born 
infants had high levels of placentally-transmitted antibody 
which declined over the first year of life and then, 
following malarial exposure, antibody levels increased over 
a period of time (89). 
The maternally acquired antibodies belong to the 
IgG class only (90). In this study, however, IgM was also 
detected along with IgG, suggesting exposure to natural 
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infection and the initial development of huirioral immunity. 
The presence of IgM therefore, does not confirm the presence 
of IgG in the infants of this area to maternal origin. 
Development of humoral immunity to malaria was found to be 
age related. The reason for age relation may be attributed 
to the increase in natural exposure to infection with time. 
In children between 2-12 years of age, the 
immunity was found to be more significant as compared to the 
infants (0-2 years) in all the study groups. The highest IgG 
and IgM titres were 1:1280 and 1:640 in children (2-14 
years) compared to only 1:40 for both IgG and IgM in infants 
(0-2 years) . 
A study carried out by McGregor £i aJ. in 1956 (91) 
led to the finding that malaria exerted its maximal effects 
in the first 18 months of life and that by the age of 3 
years the unprotected children had developed a considerable 
immunity to the disease as witnessed by their ability to 
live asymptomatica1ly with fairly dense parasitemia. 
In a subsequent study on IFA response in Gambian 
population, McGregor SLL aJ. (86) showed that the fluorescent 
antibody levels were high in newborns but declined in weeks 
following birth. Such titres remained low for the remainder 
first year of life and thereafter rose progressively 
throughout childhood into adult life. The studies of Collins 
Hh 
et SLL (92,93) in areas of Nigeria and Malaysia, which were 
hyperencieiriic for malaria, have also shown this increase m 
[FA response with age. The highest IFA titre of 1:160 m EL^  
falciparum infections was shown among children upto 5 years 
uf age and thereafter increasing to a 2-fold rise in titre 
value of 1 320 m children bt^ 'twoen 6-lU years of age in 
children 11 years and above a further 2-fold increase m 
titre value was observed m the results of Collins i±L 9.1, 
yielding the highest titre of l:b'40. The results of these 
findings are m agreement with the results of our study 
showing an increase in malaria antibody levels m children 
with age. 
The IgM levels were highest in the slide-proven 
cases of vivax malaria This may be more likely because of 
the beginning of initial exposure to malaria in the lower 
age groups (2-5 years), although such a distinction has not 
been shown in the present study The initial exposure 
results in the production of IgM which precedes the 
appearance of IgG on primary encounter with a parasite <> 90 ) . 
Biswas and his colleagues carried out a survey on 
the natural occurrence of malarial antibodies in different 
regions of Northern India (,53) In this age based survey, it 
was found that in District Hand la of Jabalpur (Madhya 
Pradesh) only 28% samples were detected positive for IgG, 
whereas 57% samples showed the presence of IgM, indicating 
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an active transmission of irialaria in that area at the time 
of sample collection. They further found that in most 
individuals with active infections, IgM was detectable. But 
in persons with recent attack of the disease both IgM and 
IgG levels were elevated. 
The observation documented by Tobie SLL aJL in 1966 
(94) showed that the initial production of IgM followed by 
IgG antibody occurs rather early in response to the 
infection by Plasmodium. Again, these findings are in 
agreement with our results where IgM levels were highest at 
the time when parasitemia had risen to detectable levels. 
The highest levels of IgG were recorded in 
children 15 to 90 days after the initial attack of vivax 
malaria. Brown ei ai in 1983 (95) reported that in majority 
of patients, convalescence was associated with an increase 
in antibody titre. Tobie el. sJL (56) carried out a study on 
healthy American volunteers (with no previous malarial 
experience), by infecting them with bites of heavily 
infected Anopheles freeborni mosquitoes with E_^  vivax. The 
above workers showed that the maximum antibody titre was 
obtained from individuals 8 days after infection, and was 
maintained for approximately 3 weeks after which the titre 
had gradually begun to decline following chemotherapy. 
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Healthy children (2-14 years) were shown to 
possess higher IgG and IgM titres when compared to healthy 
infants (0-2 years). Similar report was provided in a study 
of Voller & Draper in 1982 (17). This study showed that in 
endemic areas virtually all children, aged 2 years and over, 
exposed to natural infection by Plasmodium had detectable 
levels of specific antibodies. Adults (15-56 years) were 
also included in this study. In these cases the levels of 
antibodies (IgG and IgM) were found to show a positive 
correlation with age. An illustration of the age related 
increase in the IgG levels among the healthy residents of 
the study area is given in Figure 3. Since malaria 
antibodies in a population reflect a cumulative experience 
of exposure to the parasite over the previous years, an age 
related increase in the titres is almost always expected. A 
study undertaken by Kumar eJ^  ai in 1986 (96), to evaluate 
the role of seroepidemiology in the detection of malaria in 
and around Delhi also showed a definite trend towards age-
related increase in .serum titres of malarial antibodie.s. 
Voller & Draper (17) further stated that a 
resident of a country where malaria is endemic and who is, 
or has been, repeatedly infected and who receives minimal 
treatment, is likely to develop higher levels of antibodies 
with a very wide spectrum of reactivity. This report was 
further confirmed by the extensive studies on Gambians 
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(85). The investigations showed that the prevalence and 
number of precipitin bands in the agar-gel diffusion test 
for malaria antibody detection increases with age, 
reflecting the exposure of the community and the development 
of immunity to malaria in adults of endemic areas. 
Similarly, in a study carried out in Nigeria by Molineaux 
and Gramiccia in 1980 (97), it was found that a positive 
association occurred between serology and parasitaemia, 
indicating exposure and infection while in older people s 
negative association occurred, indicating the development of 
immunity with age. 
The findings of the present study relate well with 
above observations of the IgG levels in both slide-proven 
cases of vivax malaria and in healthy adult individiLals, who 
were found to be similar. The overall IgG positivity however 
does not show a strongly positive correlation with the slide 
positivity for E.. vivax in adults. But the antibodies of the 
IgM class showed a positive correlation with infected 
indiviudals with slide-proven vivax malaria. 
Reinfection or relapse leads to a very rapid rise 
in antibody titres to even higher levels than those achieved 
in the initial infection and these levels persist for longer 
period (19,22,56,86). As expected, the individuals in this 
study with relapses and in whom post recovery follow-up 
tests were run also showed elevated levels of IgG reaching 
upto a titre of 1:1280. However, some cases of relapses were 
found to have a higher titre of IgM in comparison to IgG 
levels ( the actual data of relapse has not been shown of 
the individuals separately), indicating that the relapse may 
actually be a reinfection due to a heterologous strain of 
the parasite. More likely, it was not a relapse but 
reinfection with the same species but probably due to a 
different strain of the parasite. 
IgH levels were found to be higher in most 
infected sera and a few negative sera from healthy 
individuals, denoting an active transmission of the disease 
in our study area during the time of sample collection. 
IgA fraction of serum immunoglobulins was also 
detected in a few samples tested from all age groups of 
subjects with slide-proven vivax malaria, clinically 
suspected malaria (slide negative), as well as in post 
recovery cases and healthy individuals, randomly. A low 
titre level of specific IgA to E.. vivax was detected, 
however its significance in malaria immunity is not clear. 
The occurrence of IgA in response to infection by 
Plasmodium has been recorded m various studies. Tobie SLL aA. 
in 1966 (94) observed a little change in the specific IgA 
during £.. vivax infections. Targett in 1970 (98) used class 
specific conjugates for IFA test in his study on falciparum 
R3 
irialaria in Gambia and found that sera of the residents had 
significant amounts of antibodies of IgG and IgM fractions 
with lesser amounts of IgA. 
Collins ei ai in 1971 (99) also used 
immunoglobulin class-specific conjugates for IFA test and 
were able to measure antibody contents of IgG, IgM and IgA 
fractions separately. The IgM and IgA antibodies were found 
to be more transient, but IgG antibody was found to be much 
more persistent. 
The significance of IgA in malaria infections is 
not yet clear. However in a study on animal models, 
Stechschulte SLL SA. in 1969 (100) found that most of the 
protective activity of hyperimmune rat serum resided in the 
IgA and IgG components of the 7 S immunoglobulin. 
Finally, an observation was also made on a small 
scale, in which investigations pertaining to the effect of 
chemotherapy in slide-proven malaria were carried out (Table 
IV). These results indicate the decline in IgG levels after 
C-hemotherapy. IgM levels were found to be less affected in 
the same individual after chemotherapy. A report from Voller 
& Draper (17) is in agreement with our findings, indicating 
that antibodies decrease rapidly to undetectable levels in 
individuals following therapeutic cure. 
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In an earlier observation, Biswas eJL SLL (53) 
measured an increased level of IgH in acute infections and 
also in samples taken after antimalarial treatment in 
individuals living in villages of Ghaziabad (U.P.). However, 
the results of our study are somewhat contradictory to the 
findings of Biswas £i. al> who further indicated that 
elevated IgG levels were found in individuals with repeated 
attacks of malaria and also after the administration of 
chemotherapy, 
4.2 CONCLUSION 
The above study could thus be concluded as 
follows: 
1. The study indicates that there is a positive 
correlation of the antibody levels increasing with age. 
2. Also, the IgG levels do not show a positive correlation 
with the slide positivity of the individuals in the 
various age groups, whereas the IgM levels show a 
positive correlation with the slide positivity and also 
in people after treatment. 
3. It was also found that high titres of IgM in the 
healthy adults were amply demonstrated, indicating the 
existence of significant numbers of E-._ vivax strains 
and hence proves the endemicity of the area. 
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4. From this study, it was further concluded that 
alongwith IgG, the detection of IgM antibodies by IFA 
tests can also be done in endemic populations. 
The present study was an initial step in providing 
some idea of antibody profiles in cases of vivax malaria in 
the malaria endemic regions of the Aligarh District. It is 
more than obvious at this stage that finer details could be 
obtained through a similar study with a larger sample. The 
sample collection can thus be carried out over a longer time 
period to include the seasonal variation trends in malaria 
transmission. The resulting antibody levels can be compiled,, 
areawise, from different parts of the state as well. This 
should provide some helpful baseline information which could 
be usefully employed for monitoring the various strategies 
brought into action for malaria control, and for other 
eradication programmes in the future. These findings would 
assume special significance when an asexual blood stage 
vaccine against malaria becomes available for use, whenever 
and wherever that may be possible. 
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APPENDIX 
1. PREPARATION OF THICK AND THIN BLOOD SMEARS FOR 
MICROSCOPICAL DIAGNOSIS OF MALARIA (101) 
Specimen 
Anticoagulated venous blood or non-anticoaguiated 
capillary blood froiri skin puncture can be used. The 
parasites are usually most numerous in the blood 
towards the end of a malarial attack. The blood should 
always be collected before antimalarial drugs are 
administered. 
(a) Thin Smear Preparation 
A drop of blood is transferred on to a clean, grease 
free slide of 25 mm x 75 mm dimensions at about 15 to 
20 cm away from the short edge of the slide. With a 
thumb and index finger of the left hand, the two edges 
of the slide are held lengthwise. The spreader slide is 
held with the right hand keeping an approximate angle 
of 30° to 45° between the two slides. The spreader is 
drawn back until it touches the drop of the blood. The 
blood is let to run along the edge of the spreader and 
the spreader is then pushed to the end of the slide 
with a smooth and quick movement. All the blood should 
be used before the spreader reaches the end of the 
slide. The spreader is kept between 30° to 45° 
throughout the process. A good slide should have the 
smear occupy the central portion of the slide with 
clear margins on all sides of the slide. The smear is 
dried and fixed before staining, 
(b) Thick Smear Preparation 
A large drop of blood is applied on to a clean, grease 
free glass slide. Using the corner of a second slide 
or a coverslip, the drop of blood is spread over an 
area of about 1 cm, the smear should have even 
thickness and should appear translucent when wet. The 
smear is air dried for about 3(D minutes before 
staining. Thick smears are not fixed. 
2. PROFORMA FOR BLOOD COLLECTION FOR MALARIA SEROLOGY 
Name : 
Age/Sex : 
Peripheral Blood Smear : 
Positive - E_ vivax/E,^ falciparum 
Negative 
Antimalarial Chemotherapy Administered : Yes/Ho 
Relapse/Primary infection 
Date/s of Previous Episode/s of Malaria (if any) : 
Slide Results in Previous Malarial Attack : 
Positive - E_ vivax/£-^ falciparum 
Negative 
Any Chemotherapy Administered in the Previous Malarial 
Experience : Yes/No 
